Skip to main content

2014 | OriginalPaper | Buchkapitel

51. Alzheimerʼs Disease

verfasst von : Reinhard Schliebs

Erschienen in: Springer Handbook of Bio-/Neuroinformatics

Verlag: Springer Berlin Heidelberg

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Alzheimerʼ s disease (AD) is the most common neurodegenerative disorder in late life which is clinically characterized by dementia and progressive cognitive impairments with presently no effective treatment. This chapter summarizes recent progress achieved during the last decades in understanding the pathogenesis of AD. Basing on the pathomorphological hallmarks (senile amyloid plaque deposits, occurance of neurofibrillary tangles as hyperphosphorylated tau protein in cerebral cortex and hippocampus) and other consistent features of the disease (neurodegeneration, cholinergic dysfunction, vascular impairments), the mayor hypotheses of cause and development of the sporadic, not genetically inherited, AD are described. Finally, to reflect the disease in its entirety and internal connective relationships, the different pathogenetic hypotheses are tentatively combined to describe the interplay of the essential features of AD and their mutually influencing pathogenetic processes in a unified model. Such a unified approach may provide a basis to model pathogenesis and progression of AD by application of computational methods such as the recently introduced novel research framework for building probabilistic computational neurogenetic models (pCNGM) by Kasabov and coworkers [51.1].

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
51.1.
Zurück zum Zitat N.K. Kasabov, R. Schliebs, H. Kojima: Probabilistic computational neurogenetic modeling: From cognitive systems to Alzheimerʼs disease, IEEE Trans. Auton. Mental Dev. 3, 1–12 (2011)CrossRef N.K. Kasabov, R. Schliebs, H. Kojima: Probabilistic computational neurogenetic modeling: From cognitive systems to Alzheimerʼs disease, IEEE Trans. Auton. Mental Dev. 3, 1–12 (2011)CrossRef
51.2.
Zurück zum Zitat A. Alzheimer: Über eine eigenartige Erkrankung der Hirnrinde, Allg. Z. Psychiatr. Psychisch-Gerichtl. Med. 64, 146–148 (1907) A. Alzheimer: Über eine eigenartige Erkrankung der Hirnrinde, Allg. Z. Psychiatr. Psychisch-Gerichtl. Med. 64, 146–148 (1907)
51.3.
Zurück zum Zitat G.G. Glenner, C.W. Wong: Alzheimerʼs disease and Downʼs syndrome: Sharing of a unique cerebrovascular amyloid fibril protein, Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984)CrossRef G.G. Glenner, C.W. Wong: Alzheimerʼs disease and Downʼs syndrome: Sharing of a unique cerebrovascular amyloid fibril protein, Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984)CrossRef
51.4.
Zurück zum Zitat C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, K. Beyreuther: Amyloid plaque core protein in Alzheimer disease and down syndrome, Proc. Natl. Acad. Sci. USA 82, 4245–4249 (1985)CrossRef C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, K. Beyreuther: Amyloid plaque core protein in Alzheimer disease and down syndrome, Proc. Natl. Acad. Sci. USA 82, 4245–4249 (1985)CrossRef
51.5.
Zurück zum Zitat J. Kang, H.G. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K.H. Grzeschik, G. Multhaup, K. Beyreuther, B. Müller-Hill: The precursor of Alzheimerʼs disease amyloid A4 protein resembles a cell-surface receptor, Nature 325, 733–736 (1987)CrossRef J. Kang, H.G. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K.H. Grzeschik, G. Multhaup, K. Beyreuther, B. Müller-Hill: The precursor of Alzheimerʼs disease amyloid A4 protein resembles a cell-surface receptor, Nature 325, 733–736 (1987)CrossRef
51.6.
Zurück zum Zitat D. Goldgaber, M.I. Lerman, O.W. McBride, U. Saffiotti, D.C. Gajdusek: (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimerʼs disease, Science 235, 877–880 (2006)CrossRef D. Goldgaber, M.I. Lerman, O.W. McBride, U. Saffiotti, D.C. Gajdusek: (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimerʼs disease, Science 235, 877–880 (2006)CrossRef
51.7.
Zurück zum Zitat N.K. Robakis, N. Ramakrishna, G. Wolfe, H.M. Wisniewski: Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides, Proc. Natl. Acad. Sci. USA 84, 4190–4194 (1987)CrossRef N.K. Robakis, N. Ramakrishna, G. Wolfe, H.M. Wisniewski: Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides, Proc. Natl. Acad. Sci. USA 84, 4190–4194 (1987)CrossRef
51.8.
Zurück zum Zitat R.E. Tanzi, J.F. Gusella, P.C. Watkins, G.A. Bruns, P. St George-Hyslop, M.L. Van Keuren, D. Patterson, S. Pagan, D.M. Kurnit, R.L. Neve: Amyloid β protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus, Science 235, 880–884 (1987)CrossRef R.E. Tanzi, J.F. Gusella, P.C. Watkins, G.A. Bruns, P. St George-Hyslop, M.L. Van Keuren, D. Patterson, S. Pagan, D.M. Kurnit, R.L. Neve: Amyloid β protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus, Science 235, 880–884 (1987)CrossRef
51.10.
Zurück zum Zitat K. Herrup: Reimagining Alzheimerʼs disease–an age-based hypothesis, J. Neurosci. 30, 16755–16762 (2010)CrossRef K. Herrup: Reimagining Alzheimerʼs disease–an age-based hypothesis, J. Neurosci. 30, 16755–16762 (2010)CrossRef
51.11.
Zurück zum Zitat R.S. Turner: Alzheimerʼs disease, Semin. Neurol. 26, 499–506 (2006)CrossRef R.S. Turner: Alzheimerʼs disease, Semin. Neurol. 26, 499–506 (2006)CrossRef
51.12.
Zurück zum Zitat R.J. Castellani, R.K. Rolston, M.A. Smith: Alzheimer disease, Dis. Mon. 56, 484–546 (2010)CrossRef R.J. Castellani, R.K. Rolston, M.A. Smith: Alzheimer disease, Dis. Mon. 56, 484–546 (2010)CrossRef
51.13.
Zurück zum Zitat G.G. Glenner, C.W. Wong, V. Quaranta, E.D. Eanes: The amyloid deposits in Alzheimerʼs disease: Their nature and pathogenesis, Appl. Pathol. 2, 357–369 (1984) G.G. Glenner, C.W. Wong, V. Quaranta, E.D. Eanes: The amyloid deposits in Alzheimerʼs disease: Their nature and pathogenesis, Appl. Pathol. 2, 357–369 (1984)
51.14.
Zurück zum Zitat I. Grundke-Iqbal, K. Iqbal, Y.C. Tung, M. Quinlan, H.M. Wisniewski, L.I. Binder: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc. Natl. Acad. Sci. USA 83, 4913–4917 (1986)CrossRef I. Grundke-Iqbal, K. Iqbal, Y.C. Tung, M. Quinlan, H.M. Wisniewski, L.I. Binder: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc. Natl. Acad. Sci. USA 83, 4913–4917 (1986)CrossRef
51.15.
Zurück zum Zitat I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y.C. Tung, M.S. Zaidi, H.M. Wisniewski: Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J. Biol. Chem. 261, 6084–6089 (1986) I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y.C. Tung, M.S. Zaidi, H.M. Wisniewski: Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J. Biol. Chem. 261, 6084–6089 (1986)
51.16.
Zurück zum Zitat K. Iqbal, I. Grundke-Iqbal, A.J. Smith, L. George, Y.C. Tung, T. Zaidi: Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease, Proc. Natl. Acad. Sci. USA 86, 5646–5650 (1989)CrossRef K. Iqbal, I. Grundke-Iqbal, A.J. Smith, L. George, Y.C. Tung, T. Zaidi: Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease, Proc. Natl. Acad. Sci. USA 86, 5646–5650 (1989)CrossRef
51.17.
Zurück zum Zitat R. Lee, P. Kermani, K.K. Teng, B.L. Hempstead: Regulation of cell survival by secreted proneurotrophins, Science 294, 1945–1948 (2001)CrossRef R. Lee, P. Kermani, K.K. Teng, B.L. Hempstead: Regulation of cell survival by secreted proneurotrophins, Science 294, 1945–1948 (2001)CrossRef
51.18.
Zurück zum Zitat K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong, S. Khatoon, B. Li, F. Liu, A. Rahman, H. Tanimukai, I. Grundke-Iqbal: Tau pathology in Alzheimer disease and other tauopathies, Biochim. Biophys. Acta 1739, 198–210 (2005)CrossRef K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong, S. Khatoon, B. Li, F. Liu, A. Rahman, H. Tanimukai, I. Grundke-Iqbal: Tau pathology in Alzheimer disease and other tauopathies, Biochim. Biophys. Acta 1739, 198–210 (2005)CrossRef
51.19.
Zurück zum Zitat A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, K. Iqbal: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc. Natl. Acad. Sci. USA 98, 6923–6928 (2001)CrossRef A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, K. Iqbal: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc. Natl. Acad. Sci. USA 98, 6923–6928 (2001)CrossRef
51.20.
Zurück zum Zitat K.R. Patterson, C. Remmers, Y. Fu, S. Brooker, N.M. Kanaan, L. Vana, S. Ward, J.F. Reyes, K. Philibert, M.J. Glucksman, L.I. Binder: Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease, J. Biol. Chem. 286, 23063–23076 (2011)CrossRef K.R. Patterson, C. Remmers, Y. Fu, S. Brooker, N.M. Kanaan, L. Vana, S. Ward, J.F. Reyes, K. Philibert, M.J. Glucksman, L.I. Binder: Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease, J. Biol. Chem. 286, 23063–23076 (2011)CrossRef
51.21.
Zurück zum Zitat C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, E. Jones: Alzheimerʼs disease, Lancet 377, 1019–1031 (2011)CrossRef C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, E. Jones: Alzheimerʼs disease, Lancet 377, 1019–1031 (2011)CrossRef
51.22.
Zurück zum Zitat M.S. Wolfe: Tau mutations in neurodegenerative diseases, J. Biol. Chem. 284, 6021–6025 (2009)CrossRef M.S. Wolfe: Tau mutations in neurodegenerative diseases, J. Biol. Chem. 284, 6021–6025 (2009)CrossRef
51.23.
Zurück zum Zitat M. Goedert, M.G. Spillantini: A century of Alzheimerʼs disease, Science 314, 777–781 (2006)CrossRef M. Goedert, M.G. Spillantini: A century of Alzheimerʼs disease, Science 314, 777–781 (2006)CrossRef
51.24.
Zurück zum Zitat S.A. Small, K. Duff: Linking Aβ and tau in late-onset Alzheimerʼs disease: A dual pathway hypothesis, Neuron 60, 534–542 (2008)CrossRef S.A. Small, K. Duff: Linking Aβ and tau in late-onset Alzheimerʼs disease: A dual pathway hypothesis, Neuron 60, 534–542 (2008)CrossRef
51.25.
Zurück zum Zitat L. Bertram, C.M. Lill, R.E. Tanzi: The genetics of Alzheimer disease: Back to the future, Neuron 68, 270–281 (2010)CrossRef L. Bertram, C.M. Lill, R.E. Tanzi: The genetics of Alzheimer disease: Back to the future, Neuron 68, 270–281 (2010)CrossRef
51.26.
Zurück zum Zitat E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines, M.A. Pericak-Vance: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimerʼs disease in late onset families, Science 261, 921–923 (1993)CrossRef E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines, M.A. Pericak-Vance: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimerʼs disease in late onset families, Science 261, 921–923 (1993)CrossRef
51.27.
Zurück zum Zitat A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan, M.J. Alberts, C. Hulette, B. Crain, D. Goldgaber, A.D. Roses: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimerʼs disease, Neurology 43, 467–1472 (1993)CrossRef A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan, M.J. Alberts, C. Hulette, B. Crain, D. Goldgaber, A.D. Roses: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimerʼs disease, Neurology 43, 467–1472 (1993)CrossRef
51.28.
Zurück zum Zitat Y. Huang: Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimerʼs disease, Trends Mol. Med. 16, 287–294 (2010)CrossRef Y. Huang: Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimerʼs disease, Trends Mol. Med. 16, 287–294 (2010)CrossRef
51.29.
Zurück zum Zitat E. Rogaeva, Y. Meng, J.H. Lee, Y. Gu, T. Kawarai, F. Zou, T. Katayama, C.T. Baldwin, R. Cheng, H. Hasegawa, F. Chen, N. Shibata, K.L. Lunetta, R. Pardossi-Piquard, C. Bohm, Y. Wakutani, L.A. Cupples, K.T. Cuenco, R.C. Green, L. Pinessi, I. Rainero, S. Sorbi, A. Bruni, R. Duara, R.P. Friedland, R. Inzelberg, W. Hampe, H. Bujo, Y.Q. Song, O.M. Andersen, T.E. Willnow, N. Graff-Radford, R.C. Petersen, D. Dickson, S.D. Der, P.E. Fraser, G. Schmitt-Ulms, S. Younkin, R. Mayeux, L.A. Farrer, P. St George-Hyslop: The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease, Nat. Genet. 39, 168–177 (2007)CrossRef E. Rogaeva, Y. Meng, J.H. Lee, Y. Gu, T. Kawarai, F. Zou, T. Katayama, C.T. Baldwin, R. Cheng, H. Hasegawa, F. Chen, N. Shibata, K.L. Lunetta, R. Pardossi-Piquard, C. Bohm, Y. Wakutani, L.A. Cupples, K.T. Cuenco, R.C. Green, L. Pinessi, I. Rainero, S. Sorbi, A. Bruni, R. Duara, R.P. Friedland, R. Inzelberg, W. Hampe, H. Bujo, Y.Q. Song, O.M. Andersen, T.E. Willnow, N. Graff-Radford, R.C. Petersen, D. Dickson, S.D. Der, P.E. Fraser, G. Schmitt-Ulms, S. Younkin, R. Mayeux, L.A. Farrer, P. St George-Hyslop: The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease, Nat. Genet. 39, 168–177 (2007)CrossRef
51.30.
Zurück zum Zitat K. Morgan: The three new pathways leading to AD, Neuropathol. Appl. Neurobiol. 37, 353–357 (2011)CrossRef K. Morgan: The three new pathways leading to AD, Neuropathol. Appl. Neurobiol. 37, 353–357 (2011)CrossRef
51.31.
Zurück zum Zitat D.M. Bowen, C.B. Smith, P. White, A.N. Davison: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies, Brain 99, 459–496 (1976)CrossRef D.M. Bowen, C.B. Smith, P. White, A.N. Davison: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies, Brain 99, 459–496 (1976)CrossRef
51.32.
Zurück zum Zitat P. Davies, A.J. Maloney: Selective loss of central cholinergic neurons in Alzheimerʼs disease, Lancet 2, 1403 (1976)CrossRef P. Davies, A.J. Maloney: Selective loss of central cholinergic neurons in Alzheimerʼs disease, Lancet 2, 1403 (1976)CrossRef
51.33.
Zurück zum Zitat E.K. Perry, P.H. Gibson, G. Blessed, R.H. Perry, B.E. Tomlinson: Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue, J. Neurol. Sci. 34, 247–265 (1977)CrossRef E.K. Perry, P.H. Gibson, G. Blessed, R.H. Perry, B.E. Tomlinson: Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue, J. Neurol. Sci. 34, 247–265 (1977)CrossRef
51.34.
Zurück zum Zitat E.K. Perry, R.H. Perry, G. Blessed, B.E. Tomlinson: Necropsy evidence of central cholinergic deficits in senile dementia, Lancet. 1, 189 (1977)CrossRef E.K. Perry, R.H. Perry, G. Blessed, B.E. Tomlinson: Necropsy evidence of central cholinergic deficits in senile dementia, Lancet. 1, 189 (1977)CrossRef
51.35.
Zurück zum Zitat D.S. Auld, T.J. Kornecook, S. Bastianetto, R. Quirion: Alzheimerʼs disease and the basal forebrain cholinergic system: Relations to β-amyloid peptides, cognition, and treatment strategies, Prog. Neurobiol. 68, 209–245 (2002)CrossRef D.S. Auld, T.J. Kornecook, S. Bastianetto, R. Quirion: Alzheimerʼs disease and the basal forebrain cholinergic system: Relations to β-amyloid peptides, cognition, and treatment strategies, Prog. Neurobiol. 68, 209–245 (2002)CrossRef
51.36.
Zurück zum Zitat A. Nordberg: Neuroreceptor changes in Alzheimer disease, Cerebrovasc. Brain Metab. Rev. 4, 303–328 (1992) A. Nordberg: Neuroreceptor changes in Alzheimer disease, Cerebrovasc. Brain Metab. Rev. 4, 303–328 (1992)
51.37.
Zurück zum Zitat L.M. Bierer, V. Haroutunian, S. Gabriel, P.J. Knott, L.S. Carlin, D.P. Purohit, D.P. Perl, J. Schmeidler, P. Kanof, K.L. Davis: Neurochemical correlates of dementia severity in Alzheimerʼs disease: Relative importance of the cholinergic deficits, J. Neurochem. 64, 749–760 (1995)CrossRef L.M. Bierer, V. Haroutunian, S. Gabriel, P.J. Knott, L.S. Carlin, D.P. Purohit, D.P. Perl, J. Schmeidler, P. Kanof, K.L. Davis: Neurochemical correlates of dementia severity in Alzheimerʼs disease: Relative importance of the cholinergic deficits, J. Neurochem. 64, 749–760 (1995)CrossRef
51.38.
Zurück zum Zitat W. Gsell, G. Jungkunz, P. Riederer: Functional neurochemistry of Alzheimerʼs disease, Curr. Pharmacol. Des. 10, 265–293 (2004)CrossRef W. Gsell, G. Jungkunz, P. Riederer: Functional neurochemistry of Alzheimerʼs disease, Curr. Pharmacol. Des. 10, 265–293 (2004)CrossRef
51.39.
Zurück zum Zitat R.T. Bartus: On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis, Exp. Neurol. 163, 495–529 (2000)CrossRef R.T. Bartus: On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis, Exp. Neurol. 163, 495–529 (2000)CrossRef
51.40.
Zurück zum Zitat E.J. Mufson, S.E. Counts, S.E. Perez, S.D. Ginsberg: Cholinergic system during the progression of Alzheimerʼs disease: Therapeutic implications, Exp, Rev. Neurother. 8, 1703–1718 (2008)CrossRef E.J. Mufson, S.E. Counts, S.E. Perez, S.D. Ginsberg: Cholinergic system during the progression of Alzheimerʼs disease: Therapeutic implications, Exp, Rev. Neurother. 8, 1703–1718 (2008)CrossRef
51.41.
Zurück zum Zitat E.J. Mufson, S.E. Counts, M. Fahnestock, S.D. Ginsberg: Cholinotrophic molecular substrates of mild cognitive impairment in the elderly, Curr. Alzheimer Res. 4, 340–350 (2007)CrossRef E.J. Mufson, S.E. Counts, M. Fahnestock, S.D. Ginsberg: Cholinotrophic molecular substrates of mild cognitive impairment in the elderly, Curr. Alzheimer Res. 4, 340–350 (2007)CrossRef
51.42.
Zurück zum Zitat A.C. Cuello, M.A. Bruno, K.F. Bell: NGF-cholinergic dependency in brain aging, MCI and Alzheimerʼs disease, Curr. Alzheimer Res. 4, 351–358 (2007)CrossRef A.C. Cuello, M.A. Bruno, K.F. Bell: NGF-cholinergic dependency in brain aging, MCI and Alzheimerʼs disease, Curr. Alzheimer Res. 4, 351–358 (2007)CrossRef
51.43.
Zurück zum Zitat Y.W. Zhang, R. Thompson, H. Zhang, H. Xu: APP processing in Alzheimerʼs disease, Mol. Brain 4, 3 (2011), doi: 10.1186/1756-6606-4-3CrossRef Y.W. Zhang, R. Thompson, H. Zhang, H. Xu: APP processing in Alzheimerʼs disease, Mol. Brain 4, 3 (2011), doi: 10.1186/1756-6606-4-3CrossRef
51.44.
Zurück zum Zitat A. Nikolaev, T. McLaughlin, D.D. OʼLeary, M. Tessier-Lavigne: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases, Nature 457, 981–989 (2009)CrossRef A. Nikolaev, T. McLaughlin, D.D. OʼLeary, M. Tessier-Lavigne: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases, Nature 457, 981–989 (2009)CrossRef
51.45.
Zurück zum Zitat H. Li, B. Wang, Z. Wang, Q. Guo, K. Tabuchi, R.E. Hammer, T.C. Südhof, H. Zheng: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP, Proc. Natl. Acad. Sci. USA 107, 17362–17367 (2010)CrossRef H. Li, B. Wang, Z. Wang, Q. Guo, K. Tabuchi, R.E. Hammer, T.C. Südhof, H. Zheng: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP, Proc. Natl. Acad. Sci. USA 107, 17362–17367 (2010)CrossRef
51.46.
Zurück zum Zitat B. De Strooper, R. Vassar, T. Golde: The secretases: Enzymes with therapeutic potential in Alzheimer disease, Nat. Rev. Neurol. 6, 99–107 (2010)CrossRef B. De Strooper, R. Vassar, T. Golde: The secretases: Enzymes with therapeutic potential in Alzheimer disease, Nat. Rev. Neurol. 6, 99–107 (2010)CrossRef
51.47.
Zurück zum Zitat J. Hardy, D. Allsop: Amyloid deposition as the central event in the aetiology of Alzheimerʼs disease, Trends Pharmacol. Sci. 12, 383–388 (1991)CrossRef J. Hardy, D. Allsop: Amyloid deposition as the central event in the aetiology of Alzheimerʼs disease, Trends Pharmacol. Sci. 12, 383–388 (1991)CrossRef
51.48.
Zurück zum Zitat J. Hardy: The amyloid hypothesis for Alzheimerʼs disease: A critical reappraisal, J. Neurochem. 110, 1129–1134 (2009)CrossRef J. Hardy: The amyloid hypothesis for Alzheimerʼs disease: A critical reappraisal, J. Neurochem. 110, 1129–1134 (2009)CrossRef
51.49.
Zurück zum Zitat B.K. Harvey, C.T. Richie, B.J. Hoffer, M. Airavaara: Transgenic animal models of neurodegeneration based on human genetic studies, J. Neural Transm. 118, 27–45 (2011)CrossRef B.K. Harvey, C.T. Richie, B.J. Hoffer, M. Airavaara: Transgenic animal models of neurodegeneration based on human genetic studies, J. Neural Transm. 118, 27–45 (2011)CrossRef
51.50.
Zurück zum Zitat A. Thathiah, B. De Strooper: The role of G protein-coupled receptors in the pathology of Alzheimerʼs disease, Nat. Rev. Neurosci. 12, 73–87 (2011)CrossRef A. Thathiah, B. De Strooper: The role of G protein-coupled receptors in the pathology of Alzheimerʼs disease, Nat. Rev. Neurosci. 12, 73–87 (2011)CrossRef
51.51.
Zurück zum Zitat M. Pákáski, J. Kálmán: Interactions between the amyloid and cholinergic mechanisms in Alzheimerʼs disease, Neurochem. Int. 53, 103–111 (2008)CrossRef M. Pákáski, J. Kálmán: Interactions between the amyloid and cholinergic mechanisms in Alzheimerʼs disease, Neurochem. Int. 53, 103–111 (2008)CrossRef
51.52.
Zurück zum Zitat R.H. Parri, T.K. Dineley: Nicotinic acetylcholine receptor interaction with beta-amyloid: Molecular, cellular, and physiological consequences, Curr. Alzheimer Res. 7, 27–39 (2010)CrossRef R.H. Parri, T.K. Dineley: Nicotinic acetylcholine receptor interaction with beta-amyloid: Molecular, cellular, and physiological consequences, Curr. Alzheimer Res. 7, 27–39 (2010)CrossRef
51.53.
Zurück zum Zitat M.M. Mesulam: Alzheimer plaques and cortical cholinergic innervation, Neuroscience 17, 275–276 (1986)CrossRef M.M. Mesulam: Alzheimer plaques and cortical cholinergic innervation, Neuroscience 17, 275–276 (1986)CrossRef
51.54.
Zurück zum Zitat M.A. Moran, E.J. Mufson, P. Gomez-Ramos: Colocalization of cholinesterases with β-amyloid protein in aged and Alzheimerʼs brain, Acta Neuropathol. 85, 362–369 (1993)CrossRef M.A. Moran, E.J. Mufson, P. Gomez-Ramos: Colocalization of cholinesterases with β-amyloid protein in aged and Alzheimerʼs brain, Acta Neuropathol. 85, 362–369 (1993)CrossRef
51.55.
Zurück zum Zitat R.M. Nitsch, B.E. Slack, R.J. Wurtman, J.H. Growdon: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science 258, 304–307 (1992)CrossRef R.M. Nitsch, B.E. Slack, R.J. Wurtman, J.H. Growdon: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science 258, 304–307 (1992)CrossRef
51.56.
Zurück zum Zitat J.D. Buxbaum, M. Oishi, H.I. Chen, R. Pinkas-Kramarski, E.A. Jaffe, S.E. Gandy, P. Greengard: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor, Proc. Natl. Acad. Sci. USA 89, 10075–10078 (1992)CrossRef J.D. Buxbaum, M. Oishi, H.I. Chen, R. Pinkas-Kramarski, E.A. Jaffe, S.E. Gandy, P. Greengard: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor, Proc. Natl. Acad. Sci. USA 89, 10075–10078 (1992)CrossRef
51.57.
Zurück zum Zitat R.M. Nitsch, S.A. Farber, J.H. Growdon, R.J. Wurtman: Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices, Proc. Natl. Acad. Sci. USA 90, 5191–5193 (1993)CrossRef R.M. Nitsch, S.A. Farber, J.H. Growdon, R.J. Wurtman: Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices, Proc. Natl. Acad. Sci. USA 90, 5191–5193 (1993)CrossRef
51.58.
Zurück zum Zitat H.A. Ensinger, H.N. Doods, A.R. Immel-Sehr, F.J. Kuhn, G. Lambrecht, K.D. Mendla, R.E. Muller, E. Mutschler, A. Sagrada, G. Walther: WAL 2014–a muscarinic agonist with preferential neuron-stimulating properties, Life Sci. 52, 473–480 (1993)CrossRef H.A. Ensinger, H.N. Doods, A.R. Immel-Sehr, F.J. Kuhn, G. Lambrecht, K.D. Mendla, R.E. Muller, E. Mutschler, A. Sagrada, G. Walther: WAL 2014–a muscarinic agonist with preferential neuron-stimulating properties, Life Sci. 52, 473–480 (1993)CrossRef
51.59.
Zurück zum Zitat S.A. Farber, R.M. Nitsch, J.G. Schulz, R.J. Wurtman: Regulated secretion of beta-amyloid precursor protein in rat brain, J. Neurosci. 15, 7442–7451 (1995) S.A. Farber, R.M. Nitsch, J.G. Schulz, R.J. Wurtman: Regulated secretion of beta-amyloid precursor protein in rat brain, J. Neurosci. 15, 7442–7451 (1995)
51.60.
Zurück zum Zitat A. Walland, S. Burkard, R. Hammer, W. Troger: In vivo consequences of M1-receptor activation by talsaclidine, Life Sci. 60, 977–984 (1997)CrossRef A. Walland, S. Burkard, R. Hammer, W. Troger: In vivo consequences of M1-receptor activation by talsaclidine, Life Sci. 60, 977–984 (1997)CrossRef
51.61.
Zurück zum Zitat D.M. Müller, K. Mendla, S.A. Farber, R.M. Nitsch: Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain, Life Sci. 60, 985–991 (1997)CrossRef D.M. Müller, K. Mendla, S.A. Farber, R.M. Nitsch: Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain, Life Sci. 60, 985–991 (1997)CrossRef
51.62.
Zurück zum Zitat C. Hock, A. Maddalena, A. Raschig, F. Müller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Müller-Thomsen, W. Oertel, M. Wienrich, A. Signorell, C. Gonzalez-Agosti, R.M. Nitsch: Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimerʼs disease, Amyloid 10, 1–6 (2003)CrossRef C. Hock, A. Maddalena, A. Raschig, F. Müller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Müller-Thomsen, W. Oertel, M. Wienrich, A. Signorell, C. Gonzalez-Agosti, R.M. Nitsch: Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimerʼs disease, Amyloid 10, 1–6 (2003)CrossRef
51.63.
Zurück zum Zitat R.M. Nitsch: Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimerʼs disease, Amyloid 10, 1–6 (2003)CrossRef R.M. Nitsch: Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimerʼs disease, Amyloid 10, 1–6 (2003)CrossRef
51.64.
Zurück zum Zitat A.Y. Hung, C. Haass, R.M. Nitsch, W.Q. Qiu, M. Citron, R.J. Wurtman, J.H. Growdon, D.J. Selkoe: Activation of protein kinase C inhibits cellular production of the amyloid beta-protein, J. Biol. Chem. 268, 22959–22962 (1993) A.Y. Hung, C. Haass, R.M. Nitsch, W.Q. Qiu, M. Citron, R.J. Wurtman, J.H. Growdon, D.J. Selkoe: Activation of protein kinase C inhibits cellular production of the amyloid beta-protein, J. Biol. Chem. 268, 22959–22962 (1993)
51.65.
Zurück zum Zitat M. Cisse, U. Braun, M. Leitges, A. Fisher, G. Pages, F. Checler, B. Vincent: ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε, Mol. Cell Neurosci. 47, 223–232 (2011)CrossRef M. Cisse, U. Braun, M. Leitges, A. Fisher, G. Pages, F. Checler, B. Vincent: ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε, Mol. Cell Neurosci. 47, 223–232 (2011)CrossRef
51.66.
Zurück zum Zitat B.E. Slack, J. Breu, M.A. Petryniak, K. Srivastava, R.J. Wurtman: Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor, J. Biol. Chem. 270, 8337–8344 (1995)CrossRef B.E. Slack, J. Breu, M.A. Petryniak, K. Srivastava, R.J. Wurtman: Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor, J. Biol. Chem. 270, 8337–8344 (1995)CrossRef
51.67.
Zurück zum Zitat R. Haring, A. Fisher, D. Marciano, Z. Pittel, Y. Kloog, A. Zuckerman, N. Eshhar, E. Heldman: Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion, J. Neurochem. 71, 2094–2103 (1998)CrossRef R. Haring, A. Fisher, D. Marciano, Z. Pittel, Y. Kloog, A. Zuckerman, N. Eshhar, E. Heldman: Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion, J. Neurochem. 71, 2094–2103 (1998)CrossRef
51.68.
Zurück zum Zitat S. Roßner, U. Ueberham, R. Schliebs, J.R. Perez-Polo, V. Bigl: The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling, Prog. Neurobiol. 56, 541–569 (1998)CrossRef S. Roßner, U. Ueberham, R. Schliebs, J.R. Perez-Polo, V. Bigl: The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling, Prog. Neurobiol. 56, 541–569 (1998)CrossRef
51.69.
Zurück zum Zitat L. Lin, B. Georgievska, A. Mattsson, O. Isacson: Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation, Proc. Natl. Acad. Sci. USA 96, 12108–12113 (1999)CrossRef L. Lin, B. Georgievska, A. Mattsson, O. Isacson: Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation, Proc. Natl. Acad. Sci. USA 96, 12108–12113 (1999)CrossRef
51.70.
Zurück zum Zitat H. Seo, A.W. Ferree, O. Isacson: Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice, Eur J. Neurosci. 15, 498–505 (2002)CrossRef H. Seo, A.W. Ferree, O. Isacson: Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice, Eur J. Neurosci. 15, 498–505 (2002)CrossRef
51.71.
Zurück zum Zitat W. Liskowsky, R. Schliebs: Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein, Int. J. Devl. Neurosci. 24, 149–156 (2006)CrossRef W. Liskowsky, R. Schliebs: Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein, Int. J. Devl. Neurosci. 24, 149–156 (2006)CrossRef
51.72.
Zurück zum Zitat A.A. Davis, J.J. Fritz, J. Wess, J.J. Lah, A.I. Levey: Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo, J. Neurosci. 30, 4190–4196 (2010)CrossRef A.A. Davis, J.J. Fritz, J. Wess, J.J. Lah, A.I. Levey: Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo, J. Neurosci. 30, 4190–4196 (2010)CrossRef
51.73.
Zurück zum Zitat A. Caccamo, S. Oddo, L.M. Billings, K.N. Green, H. Martinez-Coria, A. Fisher, F.M. LaFerla: M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron 49, 671–682 (2006)CrossRef A. Caccamo, S. Oddo, L.M. Billings, K.N. Green, H. Martinez-Coria, A. Fisher, F.M. LaFerla: M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron 49, 671–682 (2006)CrossRef
51.74.
Zurück zum Zitat R. Medeiros, M. Kitazawa, A. Caccamo, D. Baglietto-Vargas, T. Estrada-Hernandez, D.H. Cribbs, A. Fisher, F.M. Laferla: Loss of muscarinic M(1) receptor exacerbates Alzheimerʼs disease-like pathology and cognitive decline, Am. J. Pathol. 179, 980–991 (2011)CrossRef R. Medeiros, M. Kitazawa, A. Caccamo, D. Baglietto-Vargas, T. Estrada-Hernandez, D.H. Cribbs, A. Fisher, F.M. Laferla: Loss of muscarinic M(1) receptor exacerbates Alzheimerʼs disease-like pathology and cognitive decline, Am. J. Pathol. 179, 980–991 (2011)CrossRef
51.75.
Zurück zum Zitat T. Züchner, J.R. Perez-Polo, R. Schliebs: β-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling, J. Neurosci. Res. 77, 250–257 (2004)CrossRef T. Züchner, J.R. Perez-Polo, R. Schliebs: β-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling, J. Neurosci. Res. 77, 250–257 (2004)CrossRef
51.76.
Zurück zum Zitat T.A. Kohout, R.J. Lefkowitz: Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization, Mol. Pharmacol. 63, 9–18 (2003)CrossRef T.A. Kohout, R.J. Lefkowitz: Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization, Mol. Pharmacol. 63, 9–18 (2003)CrossRef
51.77.
Zurück zum Zitat J. Liu, I. Rasul, Y. Sun, G. Wu, L. Li, R.T. Premont, W.Z. Suo: GRK5 deficiency leads to reduced hippocampal acetylcholine level via impaired presynaptic M2/M4 autoreceptor desensitization, J. Biol. Chem. 284, 19564–19571 (2009)CrossRef J. Liu, I. Rasul, Y. Sun, G. Wu, L. Li, R.T. Premont, W.Z. Suo: GRK5 deficiency leads to reduced hippocampal acetylcholine level via impaired presynaptic M2/M4 autoreceptor desensitization, J. Biol. Chem. 284, 19564–19571 (2009)CrossRef
51.78.
Zurück zum Zitat W. Zhang, A.S. Basile, J. Gomeza, L.A. Volpicelli, A.I. Levey, J. Wess: Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice, J. Neurosci. 22, 1709–1717 (2002) W. Zhang, A.S. Basile, J. Gomeza, L.A. Volpicelli, A.I. Levey, J. Wess: Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice, J. Neurosci. 22, 1709–1717 (2002)
51.79.
Zurück zum Zitat Z. Suo, M. Wu, B.A. Citron, G.T. Wong, B.W. Festoff: Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimerʼs disease: An association with early beta-amyloid accumulation, J. Neurosci. 24, 3444–3452 (2004)CrossRef Z. Suo, M. Wu, B.A. Citron, G.T. Wong, B.W. Festoff: Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimerʼs disease: An association with early beta-amyloid accumulation, J. Neurosci. 24, 3444–3452 (2004)CrossRef
51.80.
Zurück zum Zitat S. Cheng, L. Li, S. He, J. Liu, Y. Sun, M. He, K. Grasing, R.T. Premont, W.Z. Suo: GRK5 deficiency accelerates β-amyloid accumulation in Tg2576 mice via impaired cholinergic activity, J. Biol. Chem. 285, 41541–41548 (2010)CrossRef S. Cheng, L. Li, S. He, J. Liu, Y. Sun, M. He, K. Grasing, R.T. Premont, W.Z. Suo: GRK5 deficiency accelerates β-amyloid accumulation in Tg2576 mice via impaired cholinergic activity, J. Biol. Chem. 285, 41541–41548 (2010)CrossRef
51.81.
Zurück zum Zitat S. Efthimiopoulos, D. Vassilacopoulou, J.A. Ripellino, N. Tezapsidis, N.K. Robakis: Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells, Proc. Natl. Acad. Sci. USA 93, 8046–8050 (1996)CrossRef S. Efthimiopoulos, D. Vassilacopoulou, J.A. Ripellino, N. Tezapsidis, N.K. Robakis: Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells, Proc. Natl. Acad. Sci. USA 93, 8046–8050 (1996)CrossRef
51.82.
Zurück zum Zitat S.H. Kim, Y.K. Kim, S.J. Jeong, C. Haass, Y.H. Kim, Y.H. Suh: Enhanced release of secreted form of Alzheimerʼs amyloid precursor protein from PC12 cells by nicotine, Mol. Pharmacol. 52, 430–436 (1997) S.H. Kim, Y.K. Kim, S.J. Jeong, C. Haass, Y.H. Kim, Y.H. Suh: Enhanced release of secreted form of Alzheimerʼs amyloid precursor protein from PC12 cells by nicotine, Mol. Pharmacol. 52, 430–436 (1997)
51.83.
Zurück zum Zitat J. Seo, S. Kim, H. Kim, C.H. Park, S. Jeong, J. Lee, S.H. Choi, K. Chang, J. Rah, J. Koo, E. Kim, Y. Suh: Effects of nicotine on APP secretion and Aβ- or CT(105)-induced toxicity, Biol. Psychiatry 49, 240–247 (2001)CrossRef J. Seo, S. Kim, H. Kim, C.H. Park, S. Jeong, J. Lee, S.H. Choi, K. Chang, J. Rah, J. Koo, E. Kim, Y. Suh: Effects of nicotine on APP secretion and Aβ- or CT(105)-induced toxicity, Biol. Psychiatry 49, 240–247 (2001)CrossRef
51.84.
Zurück zum Zitat X.L. Qi, A. Nordberg, J. Xiu, Z.Z. Guan: The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimerʼs disease, Neurochem. Int. 51, 377–383 (2007)CrossRef X.L. Qi, A. Nordberg, J. Xiu, Z.Z. Guan: The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimerʼs disease, Neurochem. Int. 51, 377–383 (2007)CrossRef
51.85.
Zurück zum Zitat T. Utsuki, M. Shoaib, H.W. Holloway, D.K. Ingram, W.C. Wallace, V. Haroutunian, K. Sambamurti, D.K. Lahiri, N.H. Greig: Nicotine lowers the secretion of the Alzheimerʼs amyloid β-protein precursor that contains amyloid β-peptide in rat, J. Alzheimers Dis. 4, 405–415 (2002) T. Utsuki, M. Shoaib, H.W. Holloway, D.K. Ingram, W.C. Wallace, V. Haroutunian, K. Sambamurti, D.K. Lahiri, N.H. Greig: Nicotine lowers the secretion of the Alzheimerʼs amyloid β-protein precursor that contains amyloid β-peptide in rat, J. Alzheimers Dis. 4, 405–415 (2002)
51.86.
Zurück zum Zitat D.K. Lahiri, T. Utsuki, D. Chen, M.R. Farlow, M. Shoaib, D.K. Ingram, N.H. Greig: Nicotine reduces the secretion of Alzheimerʼs β-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins, Ann. N. Y. Acad. Sci. 965, 364–372 (2002)CrossRef D.K. Lahiri, T. Utsuki, D. Chen, M.R. Farlow, M. Shoaib, D.K. Ingram, N.H. Greig: Nicotine reduces the secretion of Alzheimerʼs β-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins, Ann. N. Y. Acad. Sci. 965, 364–372 (2002)CrossRef
51.87.
Zurück zum Zitat M. Mousavi, E. Hellström-Lindahl: Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro, Neurochem. Int. 54, 237–244 (2009)CrossRef M. Mousavi, E. Hellström-Lindahl: Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro, Neurochem. Int. 54, 237–244 (2009)CrossRef
51.88.
Zurück zum Zitat H.Z. Nie, S. Shi, R.J. Lukas, W.J. Zhao, Y.N. Sun, M. Yin: Activation of α7 nicotinic receptor affects APP processing by regulating secretase activity in SH-EP1-α7 nAChR-hAPP695 cells, Brain Res. 1356, 112–120 (2010)CrossRef H.Z. Nie, S. Shi, R.J. Lukas, W.J. Zhao, Y.N. Sun, M. Yin: Activation of α7 nicotinic receptor affects APP processing by regulating secretase activity in SH-EP1-α7 nAChR-hAPP695 cells, Brain Res. 1356, 112–120 (2010)CrossRef
51.89.
Zurück zum Zitat H.Z. Nie, Z.Q. Li, Q.X. Yan, Z.J. Wang, W.J. Zhao, L.C. Guo, M. Yin: Nicotine decreases beta-amyloid through regulating BACE1 transcription in SH-EP1-α4β2 nAChR-APP695 cells, Neurochem. Res. 36, 904–912 (2011)CrossRef H.Z. Nie, Z.Q. Li, Q.X. Yan, Z.J. Wang, W.J. Zhao, L.C. Guo, M. Yin: Nicotine decreases beta-amyloid through regulating BACE1 transcription in SH-EP1-α4β2 nAChR-APP695 cells, Neurochem. Res. 36, 904–912 (2011)CrossRef
51.90.
Zurück zum Zitat E. Hellstrom-Lindahl, J. Court, J. Keverne, M. Svedberg, M. Lee, A. Marutle, A. Thomas, E. Perry, I. Bednar, A. Nordberg: Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice, Eur. J. Neurosci. 19, 2703–2710 (2004)CrossRef E. Hellstrom-Lindahl, J. Court, J. Keverne, M. Svedberg, M. Lee, A. Marutle, A. Thomas, E. Perry, I. Bednar, A. Nordberg: Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice, Eur. J. Neurosci. 19, 2703–2710 (2004)CrossRef
51.91.
Zurück zum Zitat M. Srivareerat, T.T. Tran, S. Salim, A.M. Aleisa, K.A. Alkadhi: Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimerʼs disease, Neurobiol. Aging 32, 834–844 (2011)CrossRef M. Srivareerat, T.T. Tran, S. Salim, A.M. Aleisa, K.A. Alkadhi: Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimerʼs disease, Neurobiol. Aging 32, 834–844 (2011)CrossRef
51.92.
Zurück zum Zitat J.A. Court, M. Johnson, D. Religa, J. Keverne, R. Kalaria, E. Jaros, I.G. McKeith, R. Perry, J. Naslund, E.K. Perry: Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking, Neuropathol. Appl. Neurobiol. 31, 522–535 (2005)CrossRef J.A. Court, M. Johnson, D. Religa, J. Keverne, R. Kalaria, E. Jaros, I.G. McKeith, R. Perry, J. Naslund, E.K. Perry: Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking, Neuropathol. Appl. Neurobiol. 31, 522–535 (2005)CrossRef
51.93.
Zurück zum Zitat A.M. Klein, N.W. Kowall, R.J. Ferrante: Neurotoxicity and oxidative damage of β-amyloid 1–42 versus β-amyloid 1–40 in the mouse cerebral cortex, Ann. N. Y. Acad. Sci. 893, 314–320 (1999)CrossRef A.M. Klein, N.W. Kowall, R.J. Ferrante: Neurotoxicity and oxidative damage of β-amyloid 1–42 versus β-amyloid 1–40 in the mouse cerebral cortex, Ann. N. Y. Acad. Sci. 893, 314–320 (1999)CrossRef
51.94.
Zurück zum Zitat W. Härtig, A. Bauer, K. Brauer, J. Gosche, T. Hortobagyi, B. Penke, R. Schliebs, T. Harkany: Functional recovery of cholinergic basal forebrain neurons under disease conditions: Old problems, Rev. Neurosci. 13, 95–165 (2002)CrossRef W. Härtig, A. Bauer, K. Brauer, J. Gosche, T. Hortobagyi, B. Penke, R. Schliebs, T. Harkany: Functional recovery of cholinergic basal forebrain neurons under disease conditions: Old problems, Rev. Neurosci. 13, 95–165 (2002)CrossRef
51.95.
Zurück zum Zitat D.M. Walsh, D.J. Selkoe: Aβ oligomers – a decade of discovery, J. Neurochem. 101, 1172–1184 (2007)CrossRef D.M. Walsh, D.J. Selkoe: Aβ oligomers – a decade of discovery, J. Neurochem. 101, 1172–1184 (2007)CrossRef
51.96.
Zurück zum Zitat B.A. Yankner, T. Lu: Amyloid β-protein toxicity and the pathogenesis of Alzheimer disease, J. Biol. Chem. 284, 4755–4759 (2009)CrossRef B.A. Yankner, T. Lu: Amyloid β-protein toxicity and the pathogenesis of Alzheimer disease, J. Biol. Chem. 284, 4755–4759 (2009)CrossRef
51.97.
Zurück zum Zitat R. Schliebs, T. Arendt: The cholinergic system in aging and neuronal degeneration, Behav. Brain Res. 221, 555–563 (2011)CrossRef R. Schliebs, T. Arendt: The cholinergic system in aging and neuronal degeneration, Behav. Brain Res. 221, 555–563 (2011)CrossRef
51.98.
Zurück zum Zitat T. Ondrejcak, I. Klyubin, N.W. Hu, A.E. Barry, W.K. Cullen, M.J. Rowan: Alzheimerʼs disease amyloid beta-protein and synaptic function, Neuromolecular Med. 12, 13–26 (2010)CrossRef T. Ondrejcak, I. Klyubin, N.W. Hu, A.E. Barry, W.K. Cullen, M.J. Rowan: Alzheimerʼs disease amyloid beta-protein and synaptic function, Neuromolecular Med. 12, 13–26 (2010)CrossRef
51.99.
Zurück zum Zitat M.S. Parihar, G.J. Brewer: Amyloid beta as a modulator of synaptic plasticity, J. Alzheimers Dis. 22, 741–763 (2010) M.S. Parihar, G.J. Brewer: Amyloid beta as a modulator of synaptic plasticity, J. Alzheimers Dis. 22, 741–763 (2010)
51.100.
Zurück zum Zitat J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, K.H. Ashe: Natural oligomers of the amyloid-β protein specifically disrupt cognitive function, Nat. Neurosci. 8, 79–84 (2005)CrossRef J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, K.H. Ashe: Natural oligomers of the amyloid-β protein specifically disrupt cognitive function, Nat. Neurosci. 8, 79–84 (2005)CrossRef
51.101.
Zurück zum Zitat S. Lesné, M.T. Koh, L. Kotinilek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, K.H. Ashe: A specific amyloid protein assembly in the brain impairs memory, Nature 440, 352–357 (2006)CrossRef S. Lesné, M.T. Koh, L. Kotinilek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, K.H. Ashe: A specific amyloid protein assembly in the brain impairs memory, Nature 440, 352–357 (2006)CrossRef
51.102.
Zurück zum Zitat C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, C.L. Masters: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimerʼs disease, Ann. Neurol. 46, 860–866 (1999)CrossRef C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, C.L. Masters: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimerʼs disease, Ann. Neurol. 46, 860–866 (1999)CrossRef
51.103.
Zurück zum Zitat J. Apelt, A. Kumar, R. Schliebs: Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein, Brain Res. 953, 17–30 (2002)CrossRef J. Apelt, A. Kumar, R. Schliebs: Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein, Brain Res. 953, 17–30 (2002)CrossRef
51.104.
Zurück zum Zitat H.J. Lüth, J. Apelt, A. Ihunwo, R. Schliebs: Degeneration of β-amyloid-associated cholinergic structures in transgenic APPSW mice, Brain Res. 977, 16–22 (2003)CrossRef H.J. Lüth, J. Apelt, A. Ihunwo, R. Schliebs: Degeneration of β-amyloid-associated cholinergic structures in transgenic APPSW mice, Brain Res. 977, 16–22 (2003)CrossRef
51.105.
Zurück zum Zitat M. Klingner, J. Apelt, A. Kumar, D. Sorger, O. Sabri, J. Steinbach, M. Scheunemann, R. Schliebs: Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β-amyloid plaque pathology, Int. J. Devl. Neurosci. 21, 357–369 (2003)CrossRef M. Klingner, J. Apelt, A. Kumar, D. Sorger, O. Sabri, J. Steinbach, M. Scheunemann, R. Schliebs: Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β-amyloid plaque pathology, Int. J. Devl. Neurosci. 21, 357–369 (2003)CrossRef
51.106.
Zurück zum Zitat A. Bellucci, I. Luccarini, C. Scali, C. Prosperi, M.G. Giovannini, G. Pepeu, F. Casamenti: Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice, Neurobiol. Dis. 23, 260–272 (2006)CrossRef A. Bellucci, I. Luccarini, C. Scali, C. Prosperi, M.G. Giovannini, G. Pepeu, F. Casamenti: Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice, Neurobiol. Dis. 23, 260–272 (2006)CrossRef
51.107.
Zurück zum Zitat D. Van Dam, B. Marescau, S. Engelborghs, T. Cremers, J. Mulder, M. Staufenbiel, P.P. De Deyn: Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models, Neurochem. Int. 46, 409–422 (2005)CrossRef D. Van Dam, B. Marescau, S. Engelborghs, T. Cremers, J. Mulder, M. Staufenbiel, P.P. De Deyn: Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models, Neurochem. Int. 46, 409–422 (2005)CrossRef
51.108.
Zurück zum Zitat K.R. Bales, E.T. Tzavara, S. Wu, M.R. Wade, F.P. Bymaster, S.M. Paul, G.G. Nomikos: Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody, J. Clin. Invest. 116, 825–832 (2006)CrossRef K.R. Bales, E.T. Tzavara, S. Wu, M.R. Wade, F.P. Bymaster, S.M. Paul, G.G. Nomikos: Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody, J. Clin. Invest. 116, 825–832 (2006)CrossRef
51.109.
Zurück zum Zitat E. Machová, J. Jakubík, P. Michal, M. Oksman, H. Iivonen, H. Tanila, V. Dolezal: Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice, Neurobiol. Aging. 29, 368–378 (2008)CrossRef E. Machová, J. Jakubík, P. Michal, M. Oksman, H. Iivonen, H. Tanila, V. Dolezal: Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice, Neurobiol. Aging. 29, 368–378 (2008)CrossRef
51.110.
Zurück zum Zitat Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, R. Vassar: Mice deficient in BACE1, the Alzheimerʼs beta-secretase, have normal phenotype and abolished β-amyloid generation, Nat. Neurosci. 4, 231–232 (2001)CrossRef Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, R. Vassar: Mice deficient in BACE1, the Alzheimerʼs beta-secretase, have normal phenotype and abolished β-amyloid generation, Nat. Neurosci. 4, 231–232 (2001)CrossRef
51.111.
Zurück zum Zitat M. Ohno, E.A. Sametsky, L.H. Younkin, H. Oakley, S.G. Younkin, M. Citron, R. Vassar, J.F. Disterhoft: BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimerʼs disease, Neuron. 41, 27–33 (2004)CrossRef M. Ohno, E.A. Sametsky, L.H. Younkin, H. Oakley, S.G. Younkin, M. Citron, R. Vassar, J.F. Disterhoft: BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimerʼs disease, Neuron. 41, 27–33 (2004)CrossRef
51.112.
Zurück zum Zitat F. Bao, L. Wicklund, P.N. Lacor, W.L. Klein, A. Nordberg, A. Marutle: Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity, Neurobiol. Aging. 33, 825.e1–825.e13 (2012)CrossRef F. Bao, L. Wicklund, P.N. Lacor, W.L. Klein, A. Nordberg, A. Marutle: Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity, Neurobiol. Aging. 33, 825.e1–825.e13 (2012)CrossRef
51.113.
Zurück zum Zitat C. Haass, D.J. Selkoe: Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide, Cell 75, 1039–1042 (1993)CrossRef C. Haass, D.J. Selkoe: Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide, Cell 75, 1039–1042 (1993)CrossRef
51.114.
Zurück zum Zitat M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione: Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258, 126–129 (1992)CrossRef M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione: Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258, 126–129 (1992)CrossRef
51.115.
Zurück zum Zitat S. Kar, S.P. Slowikowski, D. Westaway, H.T. Mount: Interactions between β-amyloid and central cholinergic neurons: Implications for Alzheimerʼs disease, J. Psychiatry Neurosci. 29, 427–441 (2004) S. Kar, S.P. Slowikowski, D. Westaway, H.T. Mount: Interactions between β-amyloid and central cholinergic neurons: Implications for Alzheimerʼs disease, J. Psychiatry Neurosci. 29, 427–441 (2004)
51.116.
Zurück zum Zitat R.J. Wurtman: Choline metabolism as a basis for the selective vulnerability of cholinergic neurons, Trends Neurosci. 15, 117–122 (1992)CrossRef R.J. Wurtman: Choline metabolism as a basis for the selective vulnerability of cholinergic neurons, Trends Neurosci. 15, 117–122 (1992)CrossRef
51.117.
Zurück zum Zitat C. Hock, A. Maddalena, A. Raschig, F. Muller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Muller-Thomsen, W. Oertel, M. Wienrich, A. Signorell, C. Gonzalez-Agosti, M. Hoshi, A. Takashima, M. Murayama, K. Yasutake, N. Yoshida, K. Ishiguro, T. Hoshino, K. Imahori: Nontoxic amyloid β peptide 1–42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimerʼs disease, J. Biol. Chem. 272, 2038–2041 (1997)CrossRef C. Hock, A. Maddalena, A. Raschig, F. Muller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Muller-Thomsen, W. Oertel, M. Wienrich, A. Signorell, C. Gonzalez-Agosti, M. Hoshi, A. Takashima, M. Murayama, K. Yasutake, N. Yoshida, K. Ishiguro, T. Hoshino, K. Imahori: Nontoxic amyloid β peptide 1–42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimerʼs disease, J. Biol. Chem. 272, 2038–2041 (1997)CrossRef
51.118.
Zurück zum Zitat W.A. Pedersen, M.A. Kloczewiak, J.K. Blusztajn: Amyloid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain, Proc. Natl. Acad. Sci. USA 93, 8068–8071 (1996)CrossRef W.A. Pedersen, M.A. Kloczewiak, J.K. Blusztajn: Amyloid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain, Proc. Natl. Acad. Sci. USA 93, 8068–8071 (1996)CrossRef
51.119.
Zurück zum Zitat D. Hicks, D. John, N.Z. Makova, Z. Henderson, N.N. Nalivaeva, A.J. Turner: Membrane targeting, J. Neurochem. 116, 742–746 (2011)CrossRef D. Hicks, D. John, N.Z. Makova, Z. Henderson, N.N. Nalivaeva, A.J. Turner: Membrane targeting, J. Neurochem. 116, 742–746 (2011)CrossRef
51.120.
Zurück zum Zitat J.F. Kelly, K. Furukawa, S.W. Barger, M.R. Rengen, R.J. Mark, E.M. Blanc, G.S. Roth, M.P. Mattson: Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons, Proc. Natl. Acad. Sci. USA 93, 6753–6758 (1996)CrossRef J.F. Kelly, K. Furukawa, S.W. Barger, M.R. Rengen, R.J. Mark, E.M. Blanc, G.S. Roth, M.P. Mattson: Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons, Proc. Natl. Acad. Sci. USA 93, 6753–6758 (1996)CrossRef
51.121.
Zurück zum Zitat B. Wang, L. Yang, Z. Wang, H. Zheng: Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter, Proc. Natl. Acad. Sci. USA 104, 14140–14145 (2007)CrossRef B. Wang, L. Yang, Z. Wang, H. Zheng: Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter, Proc. Natl. Acad. Sci. USA 104, 14140–14145 (2007)CrossRef
51.122.
Zurück zum Zitat J. Pavia, J. Alberch, I. Alvárez, A. Toledano, M.L. de Ceballos: Repeated intracerebroventricular administration of beta-amyloid (25–35) to rats decreases muscarinic receptors in cerebral cortex, Neurosci. Lett. 278, 69–72 (2000)CrossRef J. Pavia, J. Alberch, I. Alvárez, A. Toledano, M.L. de Ceballos: Repeated intracerebroventricular administration of beta-amyloid (25–35) to rats decreases muscarinic receptors in cerebral cortex, Neurosci. Lett. 278, 69–72 (2000)CrossRef
51.123.
Zurück zum Zitat A. Thathiah, B. De Strooper: G protein-coupled receptors, cholinergic dysfunction, and Aβ toxicity in Alzheimerʼs disease, Sci. Signal. 2(93), re8 (2009) A. Thathiah, B. De Strooper: G protein-coupled receptors, cholinergic dysfunction, and Aβ toxicity in Alzheimerʼs disease, Sci. Signal. 2(93), re8 (2009)
51.124.
Zurück zum Zitat T. Chiba, M. Yamada, J. Sasabe, K. Terashita, M. Shimoda, M. Matsuoka, S. Aiso: Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons, Mol. Psychiatry 14, 206–222 (2009)CrossRef T. Chiba, M. Yamada, J. Sasabe, K. Terashita, M. Shimoda, M. Matsuoka, S. Aiso: Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons, Mol. Psychiatry 14, 206–222 (2009)CrossRef
51.125.
Zurück zum Zitat L. Burghaus, U. Schütz, U. Krempel, R.A. de Vos, E.N. Jansen Steur, A. Wevers, J. Lindstrom, H. Schröder: Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients, Mol. Brain Res. 76, 385–388 (2000)CrossRef L. Burghaus, U. Schütz, U. Krempel, R.A. de Vos, E.N. Jansen Steur, A. Wevers, J. Lindstrom, H. Schröder: Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients, Mol. Brain Res. 76, 385–388 (2000)CrossRef
51.126.
Zurück zum Zitat M. Mousavi, E. Hellström-Lindahl, Z.Z. Guan, K.R. Shan, R. Ravid, A. Nordberg: Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimerʼs disease, Neuroscience 122, 515–520 (2003)CrossRef M. Mousavi, E. Hellström-Lindahl, Z.Z. Guan, K.R. Shan, R. Ravid, A. Nordberg: Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimerʼs disease, Neuroscience 122, 515–520 (2003)CrossRef
51.127.
Zurück zum Zitat C.M. Martin-Ruiz, J.A. Court, E. Molnar, M. Lee, C. Gotti, A. Mamalaki, T. Tsouloufis, S. Tzartos, C. Ballard, R.H. Perry, E.K. Perry: Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimerʼs disease, J. Neurochem. 73, 1635–1640 (1999)CrossRef C.M. Martin-Ruiz, J.A. Court, E. Molnar, M. Lee, C. Gotti, A. Mamalaki, T. Tsouloufis, S. Tzartos, C. Ballard, R.H. Perry, E.K. Perry: Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimerʼs disease, J. Neurochem. 73, 1635–1640 (1999)CrossRef
51.128.
Zurück zum Zitat A. Wevers, H. Schröder: Nicotinic acetylcholine receptors in Alzheimerʼs disease, J. Alzheimers Dis. 1, 207–219 (1999) A. Wevers, H. Schröder: Nicotinic acetylcholine receptors in Alzheimerʼs disease, J. Alzheimers Dis. 1, 207–219 (1999)
51.129.
Zurück zum Zitat A. Nordberg: Nicotinic receptor abnormalities of Alzheimerʼs disease: Therapeutic implications, Biol. Psychiatry 49, 200–210 (2001)CrossRef A. Nordberg: Nicotinic receptor abnormalities of Alzheimerʼs disease: Therapeutic implications, Biol. Psychiatry 49, 200–210 (2001)CrossRef
51.130.
Zurück zum Zitat S.D. Buckingham, A.K. Jones, L.A. Brown, D.B. Sattelle: Nicotinic acetylcholine receptor signalling: Roles in Alzheimerʼs disease and amyloid neuroprotection, Pharmacol. Rev. 61, 39–61 (2009)CrossRef S.D. Buckingham, A.K. Jones, L.A. Brown, D.B. Sattelle: Nicotinic acetylcholine receptor signalling: Roles in Alzheimerʼs disease and amyloid neuroprotection, Pharmacol. Rev. 61, 39–61 (2009)CrossRef
51.131.
Zurück zum Zitat S. Jürgensen, S. Ferreira: Nicotinic receptors, amaloid-β, and synaptic failure in Alzheimerʼs disease, J. Mol. Neurosci. 40, 221–229 (2010)CrossRef S. Jürgensen, S. Ferreira: Nicotinic receptors, amaloid-β, and synaptic failure in Alzheimerʼs disease, J. Mol. Neurosci. 40, 221–229 (2010)CrossRef
51.132.
Zurück zum Zitat R.G. Nagele, M.R. DʼAndrea, W.J. Anderson, H.Y. Wang: Intracellular accumulation of beta-amyloid (1–42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimerʼs disease, Neuroscience 110, 199–211 (2002)CrossRef R.G. Nagele, M.R. DʼAndrea, W.J. Anderson, H.Y. Wang: Intracellular accumulation of beta-amyloid (1–42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimerʼs disease, Neuroscience 110, 199–211 (2002)CrossRef
51.133.
Zurück zum Zitat F.J. Barrantes, V. Borroni, S. Vallés: Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimerʼs disease, FEBS Lett. 584, 1856–1863 (2010)CrossRef F.J. Barrantes, V. Borroni, S. Vallés: Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimerʼs disease, FEBS Lett. 584, 1856–1863 (2010)CrossRef
51.134.
Zurück zum Zitat Z.Z. Guan, H. Miao, J.Y. Tian, C. Unger, A. Nordberg, X. Zhang: Suppressed expression of nicotinic acetylcholine receptors by nanomolar β-amyloid peptides in PC12 cells, J. Neural Transm. 108, 1417–1433 (2001)CrossRef Z.Z. Guan, H. Miao, J.Y. Tian, C. Unger, A. Nordberg, X. Zhang: Suppressed expression of nicotinic acetylcholine receptors by nanomolar β-amyloid peptides in PC12 cells, J. Neural Transm. 108, 1417–1433 (2001)CrossRef
51.135.
Zurück zum Zitat Q. Liu, H. Kawai, D.K. Berg: β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons, Proc. Natl. Acad. Sci. USA 98, 4734–4739 (2001)CrossRef Q. Liu, H. Kawai, D.K. Berg: β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons, Proc. Natl. Acad. Sci. USA 98, 4734–4739 (2001)CrossRef
51.136.
Zurück zum Zitat K.A. Alkadhi, K.H. Alzoubi, M. Srivareerat, T.T. Tran: Elevation of BACE in an Aβ rat model of Alzheimerʼs disease: Exacerbation by chronic stress and prevention by nicotine, Int. J. Neuropsychopharmacol. 28, 1–11 (2011) K.A. Alkadhi, K.H. Alzoubi, M. Srivareerat, T.T. Tran: Elevation of BACE in an Aβ rat model of Alzheimerʼs disease: Exacerbation by chronic stress and prevention by nicotine, Int. J. Neuropsychopharmacol. 28, 1–11 (2011)
51.137.
Zurück zum Zitat H.Y. Wang, D.H. Lee, M.R. DʼAndrea, P.A. Peterson, R.P. Shank, A.B. Reitz: β-Amyloid(1–42) binds to α7 nicotinic acetylcholine receptor with high affinity, Implications for Alzheimerʼs disease pathology, J. Biol. Chem. 275, 5626–5632 (2000)CrossRef H.Y. Wang, D.H. Lee, M.R. DʼAndrea, P.A. Peterson, R.P. Shank, A.B. Reitz: β-Amyloid(1–42) binds to α7 nicotinic acetylcholine receptor with high affinity, Implications for Alzheimerʼs disease pathology, J. Biol. Chem. 275, 5626–5632 (2000)CrossRef
51.138.
Zurück zum Zitat H.Y. Wang, D.H. Lee, C.B. Davis, R.P. Shank: Amyloid peptide Aβ (1–42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors, J. Neurochem. 75, 1155–1161 (2000)CrossRef H.Y. Wang, D.H. Lee, C.B. Davis, R.P. Shank: Amyloid peptide Aβ (1–42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors, J. Neurochem. 75, 1155–1161 (2000)CrossRef
51.139.
Zurück zum Zitat S. Oddo, A. Caccamo, K.N. Green, K. Liang, L. Tran, Y. Chen, F.M. Leslie, F.M. LaFerla: Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimerʼs disease, Proc. Natl. Acad. Sci. USA 102, 3046–3051 (2005)CrossRef S. Oddo, A. Caccamo, K.N. Green, K. Liang, L. Tran, Y. Chen, F.M. Leslie, F.M. LaFerla: Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimerʼs disease, Proc. Natl. Acad. Sci. USA 102, 3046–3051 (2005)CrossRef
51.140.
Zurück zum Zitat X.L. Qi, J. Xiu, K.R. Shan, Y. Xiao, R. Gu, R.Y. Liu, Z.Z. Guan: Oxidative stress induced by β-amyloid peptide (1–42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells, Neurochem. Int. 46, 613–621 (2005)CrossRef X.L. Qi, J. Xiu, K.R. Shan, Y. Xiao, R. Gu, R.Y. Liu, Z.Z. Guan: Oxidative stress induced by β-amyloid peptide (1–42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells, Neurochem. Int. 46, 613–621 (2005)CrossRef
51.141.
Zurück zum Zitat Z.Z. Guan, W.F. Yu, K.R. Shan, T. Nordman, J. Olsson, A. Nordberg: Loss of nicotinic receptors induced by β-amyloid peptides in PC12 cells: Possible mechanism involving lipid peroxidation, J. Neurosci. Res. 71, 397–406 (2003)CrossRef Z.Z. Guan, W.F. Yu, K.R. Shan, T. Nordman, J. Olsson, A. Nordberg: Loss of nicotinic receptors induced by β-amyloid peptides in PC12 cells: Possible mechanism involving lipid peroxidation, J. Neurosci. Res. 71, 397–406 (2003)CrossRef
51.142.
Zurück zum Zitat K.T. Dineley, M. Westerman, D. Bui, K. Bell, K.H. Ashe, J.D. Sweatt: β-amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimerʼs disease, J. Neurosci. 21, 4125–4133 (2001) K.T. Dineley, M. Westerman, D. Bui, K. Bell, K.H. Ashe, J.D. Sweatt: β-amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimerʼs disease, J. Neurosci. 21, 4125–4133 (2001)
51.143.
Zurück zum Zitat H.Y. Wang, W. Li, N.J. Benedetti, D.H. Lee: α7 nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation, J. Biol. Chem. 278, 31547–31553 (2003)CrossRef H.Y. Wang, W. Li, N.J. Benedetti, D.H. Lee: α7 nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation, J. Biol. Chem. 278, 31547–31553 (2003)CrossRef
51.144.
Zurück zum Zitat K.T. Dineley, K.A. Bell, D. Bui, J.D. Sweatt: β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes, J. Biol. Chem. 277, 25056–25061 (2002)CrossRef K.T. Dineley, K.A. Bell, D. Bui, J.D. Sweatt: β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes, J. Biol. Chem. 277, 25056–25061 (2002)CrossRef
51.145.
Zurück zum Zitat M. Bencherif, P. Lippiello: α7 neuronal nicotinic receptors: The missing link to understanding Alzheimerʼs etiopathology?, Med. Hypotheses 74, 281–285 (2010)CrossRef M. Bencherif, P. Lippiello: α7 neuronal nicotinic receptors: The missing link to understanding Alzheimerʼs etiopathology?, Med. Hypotheses 74, 281–285 (2010)CrossRef
51.146.
Zurück zum Zitat M. Hu, J.F. Waring, M. Gopalakrishnan, J. Li: Role of GSK-3β activation and α7 nAChRs in Aβ 1–42-induced tau phosphorylation in PC12 cells, J. Neurochem. 106, 1371–1377 (2008)CrossRef M. Hu, J.F. Waring, M. Gopalakrishnan, J. Li: Role of GSK-3β activation and α7 nAChRs in Aβ 1–42-induced tau phosphorylation in PC12 cells, J. Neurochem. 106, 1371–1377 (2008)CrossRef
51.147.
Zurück zum Zitat G. Dziewczapolski, C.M. Glogowski, E. Masliah, S.F. Heinemann: Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimerʼs disease, J. Neurosci. 29, 8805–8815 (2009)CrossRef G. Dziewczapolski, C.M. Glogowski, E. Masliah, S.F. Heinemann: Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimerʼs disease, J. Neurosci. 29, 8805–8815 (2009)CrossRef
51.148.
Zurück zum Zitat A.M. Lilja, O. Porras, E. Storelli, A. Nordberg, A. Marutle: Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimerʼs disease, J. Alzheimers Dis. 23, 335–347 (2011) A.M. Lilja, O. Porras, E. Storelli, A. Nordberg, A. Marutle: Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimerʼs disease, J. Alzheimers Dis. 23, 335–347 (2011)
51.149.
Zurück zum Zitat Y. An, X.L. Qi, J.J. Pei, Z. Tang, Y. Xiao, Z.Z. Guan: Amyloid precursor protein gene mutated at Swedish 670/671 sites in vitro induces changed expression of nicotinic acetylcholine receptors and neurotoxicity, Neurochem. Int. 57, 647–654 (2010)CrossRef Y. An, X.L. Qi, J.J. Pei, Z. Tang, Y. Xiao, Z.Z. Guan: Amyloid precursor protein gene mutated at Swedish 670/671 sites in vitro induces changed expression of nicotinic acetylcholine receptors and neurotoxicity, Neurochem. Int. 57, 647–654 (2010)CrossRef
51.150.
Zurück zum Zitat G. Niewiadomska, A. Mietelska-Porowska, M. Mazurkiewicz: The cholinergic system, nerve growth factor and the cytoskeleton, Behav. Brain Res. 221, 515–526 (2011)CrossRef G. Niewiadomska, A. Mietelska-Porowska, M. Mazurkiewicz: The cholinergic system, nerve growth factor and the cytoskeleton, Behav. Brain Res. 221, 515–526 (2011)CrossRef
51.151.
Zurück zum Zitat S. Capsoni, R. Brandi, I. Arisi, M. DʼOnofrio, A. Cattaneo: A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimerʼs disease neurodegeneration in the AD11 Anti-NGF mouse model, CNS Neurol. Disord. Drug Targets, 10, 635–647 (2011)CrossRef S. Capsoni, R. Brandi, I. Arisi, M. DʼOnofrio, A. Cattaneo: A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimerʼs disease neurodegeneration in the AD11 Anti-NGF mouse model, CNS Neurol. Disord. Drug Targets, 10, 635–647 (2011)CrossRef
51.152.
Zurück zum Zitat A. Salehi, J.D. Delcroix, P.V. Belichenko, K. Zhan, C. Wu, J.S. Valletta, R. Takimoto-Kimura, A.M. Kleschevnikov, K. Sambamurti, P.P. Chung, W. Xia, A. Villar, W.A. Campbell, L.S. Kulnane, R.A. Nixon, B.T. Lamb, C.J. Epstein, G.B. Stokin, L.S. Goldstein, C. Mobley: Increased APP expression in a mouse model of Downʼs syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron 51, 29–42 (2006)CrossRef A. Salehi, J.D. Delcroix, P.V. Belichenko, K. Zhan, C. Wu, J.S. Valletta, R. Takimoto-Kimura, A.M. Kleschevnikov, K. Sambamurti, P.P. Chung, W. Xia, A. Villar, W.A. Campbell, L.S. Kulnane, R.A. Nixon, B.T. Lamb, C.J. Epstein, G.B. Stokin, L.S. Goldstein, C. Mobley: Increased APP expression in a mouse model of Downʼs syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron 51, 29–42 (2006)CrossRef
51.153.
Zurück zum Zitat J. Fombonne, S. Rabizadeh, S. Banwait, P. Mehlen, D.E. Bredesen: Selective vulnerability in Alzheimerʼs disease: Amyloid precursor protein and p75(NTR) interaction, Ann. Neurol. 65, 294–303 (2009)CrossRef J. Fombonne, S. Rabizadeh, S. Banwait, P. Mehlen, D.E. Bredesen: Selective vulnerability in Alzheimerʼs disease: Amyloid precursor protein and p75(NTR) interaction, Ann. Neurol. 65, 294–303 (2009)CrossRef
51.154.
Zurück zum Zitat K.K. Teng, S. Felice, T. Kim, B.L. Hempstead: Understanding proneurotrophin actions: Recent advances and challenges, Dev. Neurobiol. 70, 350–359 (2010) K.K. Teng, S. Felice, T. Kim, B.L. Hempstead: Understanding proneurotrophin actions: Recent advances and challenges, Dev. Neurobiol. 70, 350–359 (2010)
51.155.
Zurück zum Zitat M. Fahnestock, G. Yu, M.D. Coughlin: ProNGF: A neurotrophic or an apoptotic molecule?, Prog. Brain Res. 146, 101–110 (2004)CrossRef M. Fahnestock, G. Yu, M.D. Coughlin: ProNGF: A neurotrophic or an apoptotic molecule?, Prog. Brain Res. 146, 101–110 (2004)CrossRef
51.156.
Zurück zum Zitat M.A. Bruno, W.C. Leon, G. Fragoso, W.E. Mushynski, G. Almazan, A.C. Cuello: Amyloid β-induced nerve growth factor dysmetabolism in Alzheimer disease, J. Neuropathol. Exp. Neurol. 68, 857–869 (2009)CrossRef M.A. Bruno, W.C. Leon, G. Fragoso, W.E. Mushynski, G. Almazan, A.C. Cuello: Amyloid β-induced nerve growth factor dysmetabolism in Alzheimer disease, J. Neuropathol. Exp. Neurol. 68, 857–869 (2009)CrossRef
51.157.
Zurück zum Zitat E.J. Coulson, L.M. May, A.M. Sykes, A.S. Hamlin: The role of the p75 neurotrophin receptor in choplinergic dysfunction in Alzheimerʼs disease, Neuroscientist 15, 317–322 (2009)CrossRef E.J. Coulson, L.M. May, A.M. Sykes, A.S. Hamlin: The role of the p75 neurotrophin receptor in choplinergic dysfunction in Alzheimerʼs disease, Neuroscientist 15, 317–322 (2009)CrossRef
51.158.
Zurück zum Zitat C. Costantini, F. Rossi, E. Formaggio, R. Bernardoni, D. Cecconi, V. Della-Bianca: Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in β-amyloid peptide-dependent cell death, J. Mol. Neurosci. 25, 141–156 (2005)CrossRef C. Costantini, F. Rossi, E. Formaggio, R. Bernardoni, D. Cecconi, V. Della-Bianca: Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in β-amyloid peptide-dependent cell death, J. Mol. Neurosci. 25, 141–156 (2005)CrossRef
51.159.
Zurück zum Zitat E.J. Coulson: Does the p75 neurotrophin receptor mediate Aβ-induced toxicity in Alzheimerʼs disease?, J. Neurochem. 98, 654–660 (2006)CrossRef E.J. Coulson: Does the p75 neurotrophin receptor mediate Aβ-induced toxicity in Alzheimerʼs disease?, J. Neurochem. 98, 654–660 (2006)CrossRef
51.160.
Zurück zum Zitat A. Sotthibundhu, A.M. Sykes, B. Fox, C.K. Underwood, W. Thangnipon, E.J. Coulson: β-Amyloid1–42 induces neuronal death through the p75 neurotrophin receptor, J. Neurosci. 28, 3941–3946 (2008)CrossRef A. Sotthibundhu, A.M. Sykes, B. Fox, C.K. Underwood, W. Thangnipon, E.J. Coulson: β-Amyloid1–42 induces neuronal death through the p75 neurotrophin receptor, J. Neurosci. 28, 3941–3946 (2008)CrossRef
51.161.
Zurück zum Zitat J.K. Knowles, J. Rajadas, T.V. Nguyen, T. Yang, M.C. LeMieux, L. Vander Griend, C. Ishikawa, S.M. Massa, T. Wyss-Coray, F.M. Longo: The p75 neurotrophin receptor promotes amyloid-beta (1–42)-induced neuritic dystrophy in vitro and in vivo, J. Neurosci. 29, 10627–10637 (2009)CrossRef J.K. Knowles, J. Rajadas, T.V. Nguyen, T. Yang, M.C. LeMieux, L. Vander Griend, C. Ishikawa, S.M. Massa, T. Wyss-Coray, F.M. Longo: The p75 neurotrophin receptor promotes amyloid-beta (1–42)-induced neuritic dystrophy in vitro and in vivo, J. Neurosci. 29, 10627–10637 (2009)CrossRef
51.162.
Zurück zum Zitat M. Yaar, S. Zhai, I. Panova, R.E. Fine, P.B. Eisenhauer, J.K. Blusztajn, I. Lopez-Coviella, B.A. Gilchrest: A cyclic peptide that binds p75(NTR) protects neurones from β amyloid (1–40)-induced cell death, Neuropathol. Appl. Neurobiol. 33, 533–543 (2007) M. Yaar, S. Zhai, I. Panova, R.E. Fine, P.B. Eisenhauer, J.K. Blusztajn, I. Lopez-Coviella, B.A. Gilchrest: A cyclic peptide that binds p75(NTR) protects neurones from β amyloid (1–40)-induced cell death, Neuropathol. Appl. Neurobiol. 33, 533–543 (2007)
51.163.
Zurück zum Zitat Y.J. Wang, X. Wang, J.J. Lu, Q.X. Li, C.Y. Gao, X.H. Liu, Y. Sun, M. Yang, Y. Lim, G. Evin, J.H. Zhong, C. Masters, X.F. Zhou: p75NTR regulates Aβ deposition by increasing Aβ production but inhibiting Aβ aggregation with its extracellular domain, J. Neurosci. 31, 2292–2304 (2011)CrossRef Y.J. Wang, X. Wang, J.J. Lu, Q.X. Li, C.Y. Gao, X.H. Liu, Y. Sun, M. Yang, Y. Lim, G. Evin, J.H. Zhong, C. Masters, X.F. Zhou: p75NTR regulates Aβ deposition by increasing Aβ production but inhibiting Aβ aggregation with its extracellular domain, J. Neurosci. 31, 2292–2304 (2011)CrossRef
51.164.
Zurück zum Zitat B. Chakravarthy, C. Gaudet, M. Ménard, T. Atkinson, L. Brown, F.M. Laferla, U. Armato, J. Whitfield: Amyloid-β peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice, J. Alzheimers Dis. 19, 915–925 (2010) B. Chakravarthy, C. Gaudet, M. Ménard, T. Atkinson, L. Brown, F.M. Laferla, U. Armato, J. Whitfield: Amyloid-β peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice, J. Alzheimers Dis. 19, 915–925 (2010)
51.165.
Zurück zum Zitat M. Goedert, R. Jakes: Mutations causing neurodegenerative tauopathies, Biochim. Biophys. Acta 1739, 240–250 (2005)CrossRef M. Goedert, R. Jakes: Mutations causing neurodegenerative tauopathies, Biochim. Biophys. Acta 1739, 240–250 (2005)CrossRef
51.166.
Zurück zum Zitat S. Oddo, A. Caccamo, M. Kitazawa, B.P. Tseng, F.M. LaFerla: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimerʼs disease, Neurobiol. Aging 24, 1063–1070 (2003)CrossRef S. Oddo, A. Caccamo, M. Kitazawa, B.P. Tseng, F.M. LaFerla: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimerʼs disease, Neurobiol. Aging 24, 1063–1070 (2003)CrossRef
51.167.
Zurück zum Zitat L.M. Billings, S. Oddo, K.N. Green, J.L. McGaugh, F.M. LaFerla: Intraneuronal Aβ causes the onset of early Alzheimerʼs disease-related cognitive deficits in transgenic mice, Neuron 45, 675–688 (2005)CrossRef L.M. Billings, S. Oddo, K.N. Green, J.L. McGaugh, F.M. LaFerla: Intraneuronal Aβ causes the onset of early Alzheimerʼs disease-related cognitive deficits in transgenic mice, Neuron 45, 675–688 (2005)CrossRef
51.168.
Zurück zum Zitat M. Kitazawa, S. Oddo, T.R. Yamasaki, K.N. Green, F.M. LaFerla: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimerʼs disease, J. Neurosci. 25, 8843–8853 (2005)CrossRef M. Kitazawa, S. Oddo, T.R. Yamasaki, K.N. Green, F.M. LaFerla: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimerʼs disease, J. Neurosci. 25, 8843–8853 (2005)CrossRef
51.169.
Zurück zum Zitat S.D. Ginsberg, S. Che, S.E. Counts, E.J. Mufson: Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimerʼs disease, J. Neurochem. 96, 1401–1408 (2006)CrossRef S.D. Ginsberg, S. Che, S.E. Counts, E.J. Mufson: Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimerʼs disease, J. Neurochem. 96, 1401–1408 (2006)CrossRef
51.170.
Zurück zum Zitat M. Mesulam: The cholinergic lesion of Alzheimerʼs disease: Pivotal factor or side show, Learn Mem. 11, 43–49 (2004)CrossRef M. Mesulam: The cholinergic lesion of Alzheimerʼs disease: Pivotal factor or side show, Learn Mem. 11, 43–49 (2004)CrossRef
51.171.
Zurück zum Zitat C. Geula, N. Nagykery, A. Nicholas, C.K. Wu: Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease, J. Neuropathol. Exp. Neurol. 67, 309–318 (2008)CrossRef C. Geula, N. Nagykery, A. Nicholas, C.K. Wu: Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease, J. Neuropathol. Exp. Neurol. 67, 309–318 (2008)CrossRef
51.172.
Zurück zum Zitat K. Belarbi, S. Burnouf, F.J. Fernandez-Gomez, J. Desmerciéres, L. Troquier, J. Brouillette, L. Tsambou, M.E. Grosjean, R. Caillierez, D. Demeyer, M. Hamdane, K. Schindowski, D. Blum, L. Buée: Loss of medial septum cholinergic neurons in THY-tau22 mouse model: What links with tau pathology?, Curr. Alzheimer Res. 8, 633–638 (2011)CrossRef K. Belarbi, S. Burnouf, F.J. Fernandez-Gomez, J. Desmerciéres, L. Troquier, J. Brouillette, L. Tsambou, M.E. Grosjean, R. Caillierez, D. Demeyer, M. Hamdane, K. Schindowski, D. Blum, L. Buée: Loss of medial septum cholinergic neurons in THY-tau22 mouse model: What links with tau pathology?, Curr. Alzheimer Res. 8, 633–638 (2011)CrossRef
51.173.
Zurück zum Zitat J.C. de la Torre: Vascular risk factor detection and control may prevent Alzheimerʼs disease, Ageing Res. Rev. 9, 218–225 (2010)CrossRef J.C. de la Torre: Vascular risk factor detection and control may prevent Alzheimerʼs disease, Ageing Res. Rev. 9, 218–225 (2010)CrossRef
51.174.
Zurück zum Zitat C. Iadecola, L. Park, C. Capone: Threats to the mind: Aging, amyloid, and hypertension, Stroke. 40(3 Suppl), S40–44 (2009)CrossRef C. Iadecola, L. Park, C. Capone: Threats to the mind: Aging, amyloid, and hypertension, Stroke. 40(3 Suppl), S40–44 (2009)CrossRef
51.175.
Zurück zum Zitat J.C. de la Torre, T. Mussivand: Can disturbed brain microcirculation cause Alzheimerʼs disease?, Neurol. Res. 15, 146–153 (1993) J.C. de la Torre, T. Mussivand: Can disturbed brain microcirculation cause Alzheimerʼs disease?, Neurol. Res. 15, 146–153 (1993)
51.176.
Zurück zum Zitat R.N. Kalaria: Vascular basis for brain degeneration: Faltering controls and risk factors for dementia, Nutr. Rev. 68(Suppl.), S74–87 (2010)CrossRef R.N. Kalaria: Vascular basis for brain degeneration: Faltering controls and risk factors for dementia, Nutr. Rev. 68(Suppl.), S74–87 (2010)CrossRef
51.177.
Zurück zum Zitat N. Nicolakakis, E. Hamel: Neurovascular function in Alzheimerʼs disease patients and experimental models, Cereb. Blood Flow Metab. 31, 1354–1370 (2011)CrossRef N. Nicolakakis, E. Hamel: Neurovascular function in Alzheimerʼs disease patients and experimental models, Cereb. Blood Flow Metab. 31, 1354–1370 (2011)CrossRef
51.178.
Zurück zum Zitat R.O. Weller, D. Boche, J.A.R. Nicoll: Microvasculature changes and cerebral amyloid angiopathy in Alzheimerʼs disease and their potential impact on therapy, Acta Neuropathol. 119, 87–102 (2009)CrossRef R.O. Weller, D. Boche, J.A.R. Nicoll: Microvasculature changes and cerebral amyloid angiopathy in Alzheimerʼs disease and their potential impact on therapy, Acta Neuropathol. 119, 87–102 (2009)CrossRef
51.179.
Zurück zum Zitat C. Cordonnier, W.M. van der Flier: Brain microbleeds and Alzheimerʼs disease: Innocent observation or key player?, Brain 134, 335–344 (2011)CrossRef C. Cordonnier, W.M. van der Flier: Brain microbleeds and Alzheimerʼs disease: Innocent observation or key player?, Brain 134, 335–344 (2011)CrossRef
51.180.
Zurück zum Zitat B.V. Zlokovic: New therapeutic targets in the neurovascular pathway in Alzheimerʼs disease, Neurotherapeutics 5, 409–414 (2008)CrossRef B.V. Zlokovic: New therapeutic targets in the neurovascular pathway in Alzheimerʼs disease, Neurotherapeutics 5, 409–414 (2008)CrossRef
51.181.
Zurück zum Zitat C.A. Hawkes, W. Härtig, J. Kacza, R. Schliebs, R.O. Weller, J.A. Nicoll, R.O. Carare: Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy, Acta Neuropathol. 121, 431–443 (2011)CrossRef C.A. Hawkes, W. Härtig, J. Kacza, R. Schliebs, R.O. Weller, J.A. Nicoll, R.O. Carare: Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy, Acta Neuropathol. 121, 431–443 (2011)CrossRef
51.182.
Zurück zum Zitat M. Merlini, E.P. Meyer, A. Ulmann-Schuler, R.M. Nitsch: Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice, Acta Neuropathol. 122, 293–311 (2011)CrossRef M. Merlini, E.P. Meyer, A. Ulmann-Schuler, R.M. Nitsch: Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice, Acta Neuropathol. 122, 293–311 (2011)CrossRef
51.183.
Zurück zum Zitat D. Paris, J. Humphrey, A. Quadros, N. Patel, R. Crescentini, F. Crawford, M. Mullan: Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimerʼs disease: Role of inflammation, Neurol. Res. 25, 642–651 (2003)CrossRef D. Paris, J. Humphrey, A. Quadros, N. Patel, R. Crescentini, F. Crawford, M. Mullan: Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimerʼs disease: Role of inflammation, Neurol. Res. 25, 642–651 (2003)CrossRef
51.184.
Zurück zum Zitat C. Iadecola: Neurovascular regulation in the normal brain and in Alzheimerʼs disease, Nat Rev. Neurosci. 5, 347–360 (2004)CrossRef C. Iadecola: Neurovascular regulation in the normal brain and in Alzheimerʼs disease, Nat Rev. Neurosci. 5, 347–360 (2004)CrossRef
51.185.
Zurück zum Zitat A. Rocchi, D. Orsucci, G. Tognoni, R. Ceravolo, G. Siciliano: The role of vascular factors in late-onset sporadic Alzheimerʼs disease. Genetic and molecular aspects, Curr. Alzheimer Res. 6, 224–237 (2009)CrossRef A. Rocchi, D. Orsucci, G. Tognoni, R. Ceravolo, G. Siciliano: The role of vascular factors in late-onset sporadic Alzheimerʼs disease. Genetic and molecular aspects, Curr. Alzheimer Res. 6, 224–237 (2009)CrossRef
51.186.
Zurück zum Zitat H.J. Milionis, M. Florentin, S. Giannopoulos: Metabolic syndrome and Alzheimerʼs disease: A link to a vascular hypothesis?, CNS Spectrums 13, 606–613 (2008) H.J. Milionis, M. Florentin, S. Giannopoulos: Metabolic syndrome and Alzheimerʼs disease: A link to a vascular hypothesis?, CNS Spectrums 13, 606–613 (2008)
51.187.
Zurück zum Zitat D.A. Snowdon, L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner, W.R. Markesbery: Brain infarction and the clinical expression of Alzheimer disease, The Nun Study, J. Am. Med. Assoc. 277, 813–817 (1997)CrossRef D.A. Snowdon, L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner, W.R. Markesbery: Brain infarction and the clinical expression of Alzheimer disease, The Nun Study, J. Am. Med. Assoc. 277, 813–817 (1997)CrossRef
51.188.
Zurück zum Zitat S.L. Cole, R. Vassar: Linking vascular disorders and Alzheimerʼs disease: Potential involvement of BACE1, Neurbiol. Aging 30, 1535–1544 (2009)CrossRef S.L. Cole, R. Vassar: Linking vascular disorders and Alzheimerʼs disease: Potential involvement of BACE1, Neurbiol. Aging 30, 1535–1544 (2009)CrossRef
51.189.
Zurück zum Zitat E.E. Smith, S.M. Greenberg: β-amyloid, blood vessels and brain function, Stroke 40, 2601–2606 (2009)CrossRef E.E. Smith, S.M. Greenberg: β-amyloid, blood vessels and brain function, Stroke 40, 2601–2606 (2009)CrossRef
51.190.
Zurück zum Zitat H.K. Shin, P.B. Jones, M. Garcia-Alloza, L. Borrelli, S.M. Greenberg, B.J. Bacskai, M.P. Frosch, B.T. Hyman, M.A. Moskowitz, C. Ayata: Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy, Brain. 130(Pt 9), 2310–2319 (2007)CrossRef H.K. Shin, P.B. Jones, M. Garcia-Alloza, L. Borrelli, S.M. Greenberg, B.J. Bacskai, M.P. Frosch, B.T. Hyman, M.A. Moskowitz, C. Ayata: Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy, Brain. 130(Pt 9), 2310–2319 (2007)CrossRef
51.191.
Zurück zum Zitat D. Paris, N. Patel, A. DelleDonne, A. Quadros, R. Smeed, M. Mullan: Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis, Neurosci. Lett. 366, 80–85 (2004)CrossRef D. Paris, N. Patel, A. DelleDonne, A. Quadros, R. Smeed, M. Mullan: Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis, Neurosci. Lett. 366, 80–85 (2004)CrossRef
51.192.
Zurück zum Zitat D. Paris, K. Townsend, A. Quadros, J. Humphrey, J. Sun, S. Brem, M. Wotoczek-Obadia, A. DelleDonne, N. Patel, D.F. Obregon, R. Crescentini, L. Abdullah, D. Coppola, A.M. Rojiani, F. Crawford, S.M. Sebti, M. Mullan: Inhibition of angiogenesis by Aβ peptides, Angiogenesis 7, 75–85 (2004)CrossRef D. Paris, K. Townsend, A. Quadros, J. Humphrey, J. Sun, S. Brem, M. Wotoczek-Obadia, A. DelleDonne, N. Patel, D.F. Obregon, R. Crescentini, L. Abdullah, D. Coppola, A.M. Rojiani, F. Crawford, S.M. Sebti, M. Mullan: Inhibition of angiogenesis by Aβ peptides, Angiogenesis 7, 75–85 (2004)CrossRef
51.193.
Zurück zum Zitat C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, P. Carmeliet: Role and therapeutic potential of VEGF in the nervous system, Physiol. Rev. 89, 607–648 (2009)CrossRef C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, P. Carmeliet: Role and therapeutic potential of VEGF in the nervous system, Physiol. Rev. 89, 607–648 (2009)CrossRef
51.194.
Zurück zum Zitat F.Y. Sun, X. Guo: Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor, J. Neurosci. Res. 79, 180–184 (2005)CrossRef F.Y. Sun, X. Guo: Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor, J. Neurosci. Res. 79, 180–184 (2005)CrossRef
51.195.
Zurück zum Zitat N. Ferrara, H.P. Gerber, J. LeCouter: The biology of VEGF and its receptors, Nat. Med. 9, 669–676 (2003)CrossRef N. Ferrara, H.P. Gerber, J. LeCouter: The biology of VEGF and its receptors, Nat. Med. 9, 669–676 (2003)CrossRef
51.196.
Zurück zum Zitat R.N. Kalaria, D.L. Cohen, D.R. Premkumar, S. Nag, J.C. LaManna, W.D. Lust: Vascular endothelial growth factor in Alzheimerʼs disease and experimental cerebral ischemia, Mol. Brain Res. 62, 101–105 (1998)CrossRef R.N. Kalaria, D.L. Cohen, D.R. Premkumar, S. Nag, J.C. LaManna, W.D. Lust: Vascular endothelial growth factor in Alzheimerʼs disease and experimental cerebral ischemia, Mol. Brain Res. 62, 101–105 (1998)CrossRef
51.197.
Zurück zum Zitat E. Tarkowski, R. Issa, M. Sjogren, A. Wallin, K. Blennow, A. Tarkowski: Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimerʼs disease and vascular dementia, Neurobiol. Aging 23, 237–243 (2002)CrossRef E. Tarkowski, R. Issa, M. Sjogren, A. Wallin, K. Blennow, A. Tarkowski: Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimerʼs disease and vascular dementia, Neurobiol. Aging 23, 237–243 (2002)CrossRef
51.198.
Zurück zum Zitat S.P. Yang, D.G. Bae, H.J. Kang, B.J. Gwag, Y.S. Gho, C.B. Chae: Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimerʼs disease, Neurobiol. Aging 25, 283–290 (2004)CrossRef S.P. Yang, D.G. Bae, H.J. Kang, B.J. Gwag, Y.S. Gho, C.B. Chae: Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimerʼs disease, Neurobiol. Aging 25, 283–290 (2004)CrossRef
51.199.
Zurück zum Zitat J.K. Ryu, T. Cho, H.B. Choi, Y.T. Wang, J.G. McLarnon: Microglial VEGF receptor response is an integral chemotactic component in Alzheimerʼs disease pathology, J. Neurosci. 29, 3–13 (2009)CrossRef J.K. Ryu, T. Cho, H.B. Choi, Y.T. Wang, J.G. McLarnon: Microglial VEGF receptor response is an integral chemotactic component in Alzheimerʼs disease pathology, J. Neurosci. 29, 3–13 (2009)CrossRef
51.200.
Zurück zum Zitat A.I. Pogue, W.J. Lukiw: Angiogenic signaling in Alzheimerʼs disease, Neuroreport 15, 1507–1510 (2004)CrossRef A.I. Pogue, W.J. Lukiw: Angiogenic signaling in Alzheimerʼs disease, Neuroreport 15, 1507–1510 (2004)CrossRef
51.201.
Zurück zum Zitat L. Thirumangalakudi, P.G. Samany, A. Owoso, B. Wiskar, P. Grammas: Angiogenic proteins are expressed by brain blood vessels in Alzheimerʼs disease, J. Alzheimer Dis. 10, 111–118 (2006) L. Thirumangalakudi, P.G. Samany, A. Owoso, B. Wiskar, P. Grammas: Angiogenic proteins are expressed by brain blood vessels in Alzheimerʼs disease, J. Alzheimer Dis. 10, 111–118 (2006)
51.202.
Zurück zum Zitat A.H. Vagnucci, W.W. Li: Alzheimerʼs disease and angiogenesis, Lancet 361, 605–608 (2003)CrossRef A.H. Vagnucci, W.W. Li: Alzheimerʼs disease and angiogenesis, Lancet 361, 605–608 (2003)CrossRef
51.203.
Zurück zum Zitat B.S. Desai, J.A. Schneider, J.L. Li, P.M. Carvey, B. Hendey: Evidence of angiogenic vessels in Alzheimerʼs disease, J. Neural Transm. 116, 587–597 (2009)CrossRef B.S. Desai, J.A. Schneider, J.L. Li, P.M. Carvey, B. Hendey: Evidence of angiogenic vessels in Alzheimerʼs disease, J. Neural Transm. 116, 587–597 (2009)CrossRef
51.204.
Zurück zum Zitat H.J. Marti, M. Bernaudin, A. Bellail, H. Schoch, M. Euler, W. Petit: Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia, Am. J. Pathol. 156, 965–976 (2000)CrossRef H.J. Marti, M. Bernaudin, A. Bellail, H. Schoch, M. Euler, W. Petit: Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia, Am. J. Pathol. 156, 965–976 (2000)CrossRef
51.205.
Zurück zum Zitat I. Stein, M. Neeman, D. Shweiki, A. Itin, E. Keshet: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes, Mol. Cell Biol. 15, 5363–5368 (1995)CrossRef I. Stein, M. Neeman, D. Shweiki, A. Itin, E. Keshet: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes, Mol. Cell Biol. 15, 5363–5368 (1995)CrossRef
51.206.
Zurück zum Zitat G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash: Vascular-specific growth factors and blood vessel formation, Nature 407, 242–248 (2000)CrossRef G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash: Vascular-specific growth factors and blood vessel formation, Nature 407, 242–248 (2000)CrossRef
51.207.
Zurück zum Zitat D. Paris, A. Quadros, N. Patel, A. DelleDonne, J. Humphrey, M. Mullan: Inhibition of angiogenesis and tumour growth by β- and γ-secretase inhibitors, Eur. J. Pharmacol. 514, 1–15 (2005)CrossRef D. Paris, A. Quadros, N. Patel, A. DelleDonne, J. Humphrey, M. Mullan: Inhibition of angiogenesis and tumour growth by β- and γ-secretase inhibitors, Eur. J. Pharmacol. 514, 1–15 (2005)CrossRef
51.208.
Zurück zum Zitat J.R. Ciallella, H. Figueiredo, V. Smith-Swintosky, J.P. McGillis: Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells, Thromb. Haemost. 81, 630–637 (1999) J.R. Ciallella, H. Figueiredo, V. Smith-Swintosky, J.P. McGillis: Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells, Thromb. Haemost. 81, 630–637 (1999)
51.209.
Zurück zum Zitat S. Bürger, M. Noack, L.P. Kirazov, E.P. Kirazov, C.L. Naydenov, E. Kouznetsova, Y. Yafai, R. Schliebs: Vascular endothelial growth factor (VEGF) affects processing of the amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain, Int. J. Dev. Neurosci. 27, 517–523 (2009)CrossRef S. Bürger, M. Noack, L.P. Kirazov, E.P. Kirazov, C.L. Naydenov, E. Kouznetsova, Y. Yafai, R. Schliebs: Vascular endothelial growth factor (VEGF) affects processing of the amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain, Int. J. Dev. Neurosci. 27, 517–523 (2009)CrossRef
51.210.
Zurück zum Zitat S. Bürger, Y. Yafai, M. Bigl, P. Wiedemann, R. Schliebs: Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the β-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice, Int. J. Dev. Neurosci. 28, 597–604 (2010)CrossRef S. Bürger, Y. Yafai, M. Bigl, P. Wiedemann, R. Schliebs: Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the β-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice, Int. J. Dev. Neurosci. 28, 597–604 (2010)CrossRef
51.211.
Zurück zum Zitat H. Girouard, C. Iadecola: Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease, J. Appl. Physiol. 100, 328–335 (2006)CrossRef H. Girouard, C. Iadecola: Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease, J. Appl. Physiol. 100, 328–335 (2006)CrossRef
51.212.
Zurück zum Zitat E. Hamel: Perivascular nerves and the regulation of cerebrovascular tone, J. Appl. Physiol. 100, 1059–1064 (2006)CrossRef E. Hamel: Perivascular nerves and the regulation of cerebrovascular tone, J. Appl. Physiol. 100, 1059–1064 (2006)CrossRef
51.213.
Zurück zum Zitat A.H. VanBeek, J.A. Claassen: The cerebrovascular role of the cholinergic neural system in Alzheimerʼs disease, Behav. Brain Res. 221, 537–542 (2003)CrossRef A.H. VanBeek, J.A. Claassen: The cerebrovascular role of the cholinergic neural system in Alzheimerʼs disease, Behav. Brain Res. 221, 537–542 (2003)CrossRef
51.214.
Zurück zum Zitat E. Vaucher, E. Hamel: Cholinergic basal forebrain neurons project to cortical microvessels in the rat: Electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry, J. Neurosci. 15, 7427–7441 (1995) E. Vaucher, E. Hamel: Cholinergic basal forebrain neurons project to cortical microvessels in the rat: Electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry, J. Neurosci. 15, 7427–7441 (1995)
51.215.
Zurück zum Zitat E. Hamel: Cholinergic modulation of the cortical microvascular bed, Prog. Brain Res. 145, 171–178 (2004)CrossRef E. Hamel: Cholinergic modulation of the cortical microvascular bed, Prog. Brain Res. 145, 171–178 (2004)CrossRef
51.216.
Zurück zum Zitat A. Elhusseiny, E. Hamel: Muscarinic–but not nicotinic–acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: A possible role for the M5 receptor subtype, J. Cereb. Blood Flow Metab. 20, 298–305 (2000)CrossRef A. Elhusseiny, E. Hamel: Muscarinic–but not nicotinic–acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: A possible role for the M5 receptor subtype, J. Cereb. Blood Flow Metab. 20, 298–305 (2000)CrossRef
51.217.
Zurück zum Zitat E. Farkas, P.G. Luiten: Cerebral microvascular pathology in aging and Alzheimerʼs disease, Prog. Neurobiol. 64, 575–611 (2001)CrossRef E. Farkas, P.G. Luiten: Cerebral microvascular pathology in aging and Alzheimerʼs disease, Prog. Neurobiol. 64, 575–611 (2001)CrossRef
51.218.
Zurück zum Zitat B. Cauli, X.K. Tong, A. Rancillac, N. Serluca, B. Lambolez, J. Rossier, E. Hamel: Cortical GABA interneurons in neurovascular coupling: Relays for subcortical vasoactive pathways, J. Neurosci. 24, 8940–8949 (2004)CrossRef B. Cauli, X.K. Tong, A. Rancillac, N. Serluca, B. Lambolez, J. Rossier, E. Hamel: Cortical GABA interneurons in neurovascular coupling: Relays for subcortical vasoactive pathways, J. Neurosci. 24, 8940–8949 (2004)CrossRef
51.219.
Zurück zum Zitat C. Humpel, J. Marksteiner: Cerebrovascular damage as a cause for Alzheimerʼs disease, Curr. Neurovasc. Res. 2, 341–347 (2005)CrossRef C. Humpel, J. Marksteiner: Cerebrovascular damage as a cause for Alzheimerʼs disease, Curr. Neurovasc. Res. 2, 341–347 (2005)CrossRef
51.220.
Zurück zum Zitat J.A. Claassen, R.W. Jansen: Cholinergically mediated augmentation of cerebral perfusion in Alzheimerʼs disease and related cognitive disorders: The cholinergic-vascular hypothesis, J. Gerontol. A Biol. Sci. Med. Sci. 61, 267–271 (2006)CrossRef J.A. Claassen, R.W. Jansen: Cholinergically mediated augmentation of cerebral perfusion in Alzheimerʼs disease and related cognitive disorders: The cholinergic-vascular hypothesis, J. Gerontol. A Biol. Sci. Med. Sci. 61, 267–271 (2006)CrossRef
51.221.
Zurück zum Zitat E. Kouznetsova, R. Schliebs: Role of cholinergic system in β-amyloid related changes of perivascular innervation of cerebral microvessels in transgenic Tg2576 Alzheimer-like mice, J. Neurochem. 101(Suppl. 1), 63 (2007) E. Kouznetsova, R. Schliebs: Role of cholinergic system in β-amyloid related changes of perivascular innervation of cerebral microvessels in transgenic Tg2576 Alzheimer-like mice, J. Neurochem. 101(Suppl. 1), 63 (2007)
51.222.
Zurück zum Zitat A. Szutowicz, H. Bielarczyk, S. Gul, P. Zieliński, T. Pawełczyk, M. Tomaszewicz: Nerve growth factor and acetyl-l-carnitine evoked shifts in acetyl-CoA and cholinergic SN56 cell Vulnerability to neurotoxic inputs, J. Neurosci. Res. 79, 185–192 (2005)CrossRef A. Szutowicz, H. Bielarczyk, S. Gul, P. Zieliński, T. Pawełczyk, M. Tomaszewicz: Nerve growth factor and acetyl-l-carnitine evoked shifts in acetyl-CoA and cholinergic SN56 cell Vulnerability to neurotoxic inputs, J. Neurosci. Res. 79, 185–192 (2005)CrossRef
51.223.
Zurück zum Zitat S.C. Correia, R.X. Santos, G. Perry, X. Zhu, P.I. Moreira, M.A. Smith: Insulin-resistant brain state: The culprit in sporadic Alzheimerʼs disease?, Ageing Res. Rev. 10, 264–273 (2011)CrossRef S.C. Correia, R.X. Santos, G. Perry, X. Zhu, P.I. Moreira, M.A. Smith: Insulin-resistant brain state: The culprit in sporadic Alzheimerʼs disease?, Ageing Res. Rev. 10, 264–273 (2011)CrossRef
51.224.
Zurück zum Zitat M. Bigl, J. Apelt, K. Eschrich, R. Schliebs: Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology, J. Neural Transm. 110, 77–94 (2003) M. Bigl, J. Apelt, K. Eschrich, R. Schliebs: Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology, J. Neural Transm. 110, 77–94 (2003)
51.225.
Zurück zum Zitat P. Ghosh, A. Kumar, B. Datta, V. Rangachari: Dynamics of protofibril elongation and association involved in Aβ42 peptide aggregation in Alzheimerʼs disease, BMC Bioinformatics 11(Suppl 6), S24 (2010)CrossRef P. Ghosh, A. Kumar, B. Datta, V. Rangachari: Dynamics of protofibril elongation and association involved in Aβ42 peptide aggregation in Alzheimerʼs disease, BMC Bioinformatics 11(Suppl 6), S24 (2010)CrossRef
51.226.
Zurück zum Zitat N.L. Fawzi, E.H. Yap, Y. Okabe, K.L. Kohlstedt, S.P. Brown, T. Head-Gordon: Contrasting disease and nondisease protein aggregation by molecular simulation, Acc. Chem. Res. 41, 1037–1047 (2008)CrossRef N.L. Fawzi, E.H. Yap, Y. Okabe, K.L. Kohlstedt, S.P. Brown, T. Head-Gordon: Contrasting disease and nondisease protein aggregation by molecular simulation, Acc. Chem. Res. 41, 1037–1047 (2008)CrossRef
51.227.
Zurück zum Zitat A.R. George, D.R. Howlett: Computationally derived structural models of the beta-amyloid found in Alzheimerʼs disease plaques and the interaction with possible aggregation inhibitors, Biopolymers 50, 733–741 (1999)CrossRef A.R. George, D.R. Howlett: Computationally derived structural models of the beta-amyloid found in Alzheimerʼs disease plaques and the interaction with possible aggregation inhibitors, Biopolymers 50, 733–741 (1999)CrossRef
51.228.
Zurück zum Zitat S.Y. Ponomarev, J. Audie: Computational prediction and analysis of the DR6-NAPP interaction, Proteins. 79, 1376–1395 (2011)CrossRef S.Y. Ponomarev, J. Audie: Computational prediction and analysis of the DR6-NAPP interaction, Proteins. 79, 1376–1395 (2011)CrossRef
51.229.
Zurück zum Zitat J. Luo, J.D. Maréchal, S. Wärmländer, A. Gräslund, A. Perálvarez-Marín: In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: Misfolding induced by frustration of the salt bridge network, PLoS Comput. Biol. 6(2), e1000663 (2010)CrossRef J. Luo, J.D. Maréchal, S. Wärmländer, A. Gräslund, A. Perálvarez-Marín: In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: Misfolding induced by frustration of the salt bridge network, PLoS Comput. Biol. 6(2), e1000663 (2010)CrossRef
51.230.
Zurück zum Zitat J.Y. Chen, E. Youn, S.D. Mooney: Connecting protein interaction data, mutations, Methods Mol. Biol. 541, 449–461 (2009)CrossRef J.Y. Chen, E. Youn, S.D. Mooney: Connecting protein interaction data, mutations, Methods Mol. Biol. 541, 449–461 (2009)CrossRef
51.231.
Zurück zum Zitat K.C. Chou, K.D. Watenpaugh, R.L. Heinrikson: A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator, Biochem. Biophys. Res. Commun. 259, 420–428 (1999)CrossRef K.C. Chou, K.D. Watenpaugh, R.L. Heinrikson: A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator, Biochem. Biophys. Res. Commun. 259, 420–428 (1999)CrossRef
51.232.
Zurück zum Zitat Y. Huang, X. Sun, G. Hu: An integrated genetics approach for identifying protein signal pathways of Alzheimerʼs disease, Comput. Methods Biomech. Biomed. Engin. 14, 371–378 (2011)CrossRef Y. Huang, X. Sun, G. Hu: An integrated genetics approach for identifying protein signal pathways of Alzheimerʼs disease, Comput. Methods Biomech. Biomed. Engin. 14, 371–378 (2011)CrossRef
51.233.
Zurück zum Zitat D.L. Cook, J.C. Wiley, J.H. Gennari: Chalkboard: Ontology-based pathway modeling and qualitative inference of disease mechanisms, Pac. Symp. Biocomput. 2007, 16–27 (2007) D.L. Cook, J.C. Wiley, J.H. Gennari: Chalkboard: Ontology-based pathway modeling and qualitative inference of disease mechanisms, Pac. Symp. Biocomput. 2007, 16–27 (2007)
51.234.
Zurück zum Zitat I. García, Y. Fall, G. Gómez, H. González-Díaz: First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines, Mol. Divers. 15, 561–567 (2011)CrossRef I. García, Y. Fall, G. Gómez, H. González-Díaz: First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines, Mol. Divers. 15, 561–567 (2011)CrossRef
51.235.
Zurück zum Zitat R. Gómez-Balderas, D.F. Raffa, G.A. Rickard, P. Brunelle, A. Rauk: Computational studies of Cu(II)/Met and Cu(I)/Met binding motifs relevant for the chemistry of Alzheimerʼs disease, J. Phys. Chem. A 109, 5498–5508 (2005)CrossRef R. Gómez-Balderas, D.F. Raffa, G.A. Rickard, P. Brunelle, A. Rauk: Computational studies of Cu(II)/Met and Cu(I)/Met binding motifs relevant for the chemistry of Alzheimerʼs disease, J. Phys. Chem. A 109, 5498–5508 (2005)CrossRef
51.236.
Zurück zum Zitat R. Singh, A. Barman, R. Prabhakar: Computational insights into aspartyl protease activity of presenilin 1 (PS1) generating Alzheimer amyloid β-peptides (Aβ40 and Aβ42), J. Phys. Chem. B. 113, 2990–2999 (2009)CrossRef R. Singh, A. Barman, R. Prabhakar: Computational insights into aspartyl protease activity of presenilin 1 (PS1) generating Alzheimer amyloid β-peptides (Aβ40 and Aβ42), J. Phys. Chem. B. 113, 2990–2999 (2009)CrossRef
51.237.
Zurück zum Zitat M. Eisenstein: Genetics: Finding risk factors, Nature 475, S20–S22 (2011)CrossRef M. Eisenstein: Genetics: Finding risk factors, Nature 475, S20–S22 (2011)CrossRef
51.238.
Zurück zum Zitat M.D. Ritchie, L.W. Hahn, J.H. Moore: Power of multifactor dimensionality reduction for detecting gene–gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity, Genet. Epidemiol. 24, 150–157 (2003)CrossRef M.D. Ritchie, L.W. Hahn, J.H. Moore: Power of multifactor dimensionality reduction for detecting gene–gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity, Genet. Epidemiol. 24, 150–157 (2003)CrossRef
51.239.
Zurück zum Zitat S.Y. Lee, Y. Chung, R.C. Elston, Y. Kim, T. Park: Log-linear model-based multifactor dimensionality reduction method to detect gene gene interactions, Bioinformatics. 23, 2589–2595 (2007)CrossRef S.Y. Lee, Y. Chung, R.C. Elston, Y. Kim, T. Park: Log-linear model-based multifactor dimensionality reduction method to detect gene gene interactions, Bioinformatics. 23, 2589–2595 (2007)CrossRef
51.240.
Zurück zum Zitat J. Andrade, M. Andersen, A. Sillén, C. Graff, J. Odeberg: The use of grid computing to drive data-intensive genetic research, Eur. J. Hum. Genet. 15, 694–702 (2007)CrossRef J. Andrade, M. Andersen, A. Sillén, C. Graff, J. Odeberg: The use of grid computing to drive data-intensive genetic research, Eur. J. Hum. Genet. 15, 694–702 (2007)CrossRef
51.241.
Zurück zum Zitat B. Liu, T. Jiang, S. Ma, H. Zhao, J. Li, X. Jiang, J. Zhang: Exploring candidate genes for human brain diseases from a brain-specific gene network, Biochem. Biophys. Res. Commun. 349, 1308–1314 (2006)CrossRef B. Liu, T. Jiang, S. Ma, H. Zhao, J. Li, X. Jiang, J. Zhang: Exploring candidate genes for human brain diseases from a brain-specific gene network, Biochem. Biophys. Res. Commun. 349, 1308–1314 (2006)CrossRef
51.242.
Zurück zum Zitat K. Heinitz, M. Beck, R. Schliebs, J.R. Perez-Polo: Toxicity mediated by soluble oligomers of β-amyloid (1–42) on cholinergic SN56.B5.G4 cells, J. Neurochem. 98, 1930–1945 (2006)CrossRef K. Heinitz, M. Beck, R. Schliebs, J.R. Perez-Polo: Toxicity mediated by soluble oligomers of β-amyloid (1–42) on cholinergic SN56.B5.G4 cells, J. Neurochem. 98, 1930–1945 (2006)CrossRef
51.243.
Zurück zum Zitat S. Joerchel, M. Raap, M. Bigl, K. Eschrich, R. Schliebs: Oligomeric β-amyloid (1–42) induces the expression of Alzheimer disease-relevant proteins in cholinergic SN56.B5.G4 cells as revealed by proteomic analysis, Int. J. Dev. Neurosci. 26, 301–308 (2006)CrossRef S. Joerchel, M. Raap, M. Bigl, K. Eschrich, R. Schliebs: Oligomeric β-amyloid (1–42) induces the expression of Alzheimer disease-relevant proteins in cholinergic SN56.B5.G4 cells as revealed by proteomic analysis, Int. J. Dev. Neurosci. 26, 301–308 (2006)CrossRef
51.244.
Zurück zum Zitat J. Li, X. Zhu, J.Y. Chen: Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts, PLoS Comput. Biol. 5(7), e1000450 (2009)CrossRef J. Li, X. Zhu, J.Y. Chen: Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts, PLoS Comput. Biol. 5(7), e1000450 (2009)CrossRef
51.245.
Zurück zum Zitat Y. He, Z. Chen, G. Gong, A. Evans: Neuronal networks in Alzheimerʼs disease, Neuroscientist 15, 333–350 (2009)CrossRef Y. He, Z. Chen, G. Gong, A. Evans: Neuronal networks in Alzheimerʼs disease, Neuroscientist 15, 333–350 (2009)CrossRef
51.246.
Zurück zum Zitat D.J. Watts, S.H. Strogatz: Collective dynamics of `small-worldʼ networks, Nature 393, 440–442 (1998)CrossRef D.J. Watts, S.H. Strogatz: Collective dynamics of `small-worldʼ networks, Nature 393, 440–442 (1998)CrossRef
51.247.
Zurück zum Zitat C.J. Stam, B.F. Jones, G. Nolte, M. Breakspear, P. Scheltens: Small-world networks and functional connectivity in Alzheimerʼs disease, Cereb. Cortex 17, 92–99 (2007)CrossRef C.J. Stam, B.F. Jones, G. Nolte, M. Breakspear, P. Scheltens: Small-world networks and functional connectivity in Alzheimerʼs disease, Cereb. Cortex 17, 92–99 (2007)CrossRef
51.248.
Zurück zum Zitat R. Tandon, S. Adak, J.A. Kaye: Neural networks for longitudinal studies in Alzheimerʼs disease, Artif. Intell. Med. 36, 245–255 (2006)CrossRef R. Tandon, S. Adak, J.A. Kaye: Neural networks for longitudinal studies in Alzheimerʼs disease, Artif. Intell. Med. 36, 245–255 (2006)CrossRef
51.249.
Zurück zum Zitat M.E. Hasselmo: A computational model of the progression of Alzheimerʼs disease, M.D. Computing 14, 181–191 (1997) M.E. Hasselmo: A computational model of the progression of Alzheimerʼs disease, M.D. Computing 14, 181–191 (1997)
51.250.
Zurück zum Zitat M.E. Hasselmo: Neuromodulation and cortical function: Modeling the physiological basis of behavior, Behav. Brain Res. 67, 1–27 (1995)CrossRef M.E. Hasselmo: Neuromodulation and cortical function: Modeling the physiological basis of behavior, Behav. Brain Res. 67, 1–27 (1995)CrossRef
51.251.
Zurück zum Zitat D. Horn, N. Levy, E. Ruppin: Neuronal-based synaptic compensation: A computational study in Alzheimerʼs disease, Neural Comput. 8, 1227–1243 (1996)CrossRef D. Horn, N. Levy, E. Ruppin: Neuronal-based synaptic compensation: A computational study in Alzheimerʼs disease, Neural Comput. 8, 1227–1243 (1996)CrossRef
51.252.
Zurück zum Zitat L. Nickels, B. Biedermann, M. Coltheart, S. Saunders, J.J. Tree: Computational modelling of phonological dyslexia: How does the DRC model fare?, Cogn. Neuropsychol. 25, 165–193 (2008)CrossRef L. Nickels, B. Biedermann, M. Coltheart, S. Saunders, J.J. Tree: Computational modelling of phonological dyslexia: How does the DRC model fare?, Cogn. Neuropsychol. 25, 165–193 (2008)CrossRef
51.253.
Zurück zum Zitat A. Serna, V. Rialle, H. Pigot: Computational representation of Alzheimerʼs disease evolution applied to a cooking activity, Stud. Health Technol. Inform. 124, 587–592 (2006) A. Serna, V. Rialle, H. Pigot: Computational representation of Alzheimerʼs disease evolution applied to a cooking activity, Stud. Health Technol. Inform. 124, 587–592 (2006)
51.254.
Zurück zum Zitat M.A. Ahmadi-Pajouh, F. Towhidkhah, S. Gharibzadeh, M. Mashhadimalek: Path planning in the hippocampo-prefrontal cortex pathway: An adaptive model based receding horizon planner, Med. Hypotheses 68, 1411–1415 (2007)CrossRef M.A. Ahmadi-Pajouh, F. Towhidkhah, S. Gharibzadeh, M. Mashhadimalek: Path planning in the hippocampo-prefrontal cortex pathway: An adaptive model based receding horizon planner, Med. Hypotheses 68, 1411–1415 (2007)CrossRef
51.255.
Zurück zum Zitat E. Ruppin, J.A. Reggia: A neural model of memory impairment in diffuse cerebral atrophy, Br. J. Psychiatry. 166, 19–28 (1995)CrossRef E. Ruppin, J.A. Reggia: A neural model of memory impairment in diffuse cerebral atrophy, Br. J. Psychiatry. 166, 19–28 (1995)CrossRef
Metadaten
Titel
Alzheimerʼs Disease
verfasst von
Reinhard Schliebs
Copyright-Jahr
2014
DOI
https://doi.org/10.1007/978-3-642-30574-0_51

Premium Partner